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This work focuses on the design and implementation of tools to characterize a 
regulatory RNA-protein network in vivo. As such, this work developed techniques to 
detect RNA-protein interactions, characterize repression of translation, and model the 
RNA-protein interaction as a means of target identification. We specifically focused on 
the RNA-protein interactions of the post transcriptional regulatory protein, CsrA, of the 
Carbon storage regulator system.  
A fluorescence based technique, named Tri-molecular Fluorescent 
Complementation (TriFC), was developed to detect RNA-protein interactions in vivo and 
demonstrated using CsrA and the sRNA, CsrB.  This tool showed sensitivity to mutations 
in CsrA that affect the affinity of the interaction. A modified version of this tool was later 
implemented to characterize mRNA-CsrA interactions as a means of identifying targets 
of CsrA. 
A translational assay was developed to detect the effect that CsrA has on the 
translational activity of mRNAs. This assay tested 241 different mRNA targets and 
identified 94 mRNAs that displayed inhibition by CsrA. Using modifications to the 
TriFC system, 32 mRNAs were observed directly interacting with CsrA.  The evidence 
from the TriFC system and the translational assay revealed 19 previously uncharacterized 
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mRNAs as targets of CsrA regulation, with the most important of these genes being the 
sigma factor rpoS. 
Lastly, a model was developed using the primary principles of CsrA interactions 
that predicts the affinity an mRNA sequence has for CsrA and the effect that CsrA would 
have on the translational activity of the mRNA. Experimental data established that 
mRNA targets with a sufficiently a high prediction of CsrA affinity are very likely to be 
true CsrA targets. The predictions for the binding site affinity were evaluated using a 
novel in vivo titration technique, and it was demonstrated that the affinity predictions 
have physical significance in describing the interaction of CsrA and the RNA. With this 
model, it will be possible to evaluate the genome of E. coli to predict CsrA’s regulatory 
effect on mRNA targets. In total, this work demonstrated generalizable tools to 
characterize RNA-protein interactions, and the specific focus on the CsrA protein makes 
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Chapter 1 
Introduction and Background Information 
1.1 INTRODUCTION 
The recognized role of cellular RNAs has greatly expanded over the years to 
include a wide diversity of regulatory actions. In bacteria, small RNAs (sRNAs) 
regulate outer membrane proteins (1), quorum sensing (2, 3), expression of virulence-
related genes (4), response to stress (5), and general control of metabolism (6).  While 
there have been over 1,000 sRNAs identified (7), only a few mechanisms are known 
in detail. For instance, it is understood that sRNAs can function by 1) base-pairing 
with mRNAs to prevent protein translation and promote degradation, 2) sequestering 
proteins into ribonucleoprotein complexes to prevent their activity, or 3) directly 
catalyzing mRNA and protein degradation (see for review: (8, 9)). Additionally, 
RNA-based regulation employs modular recognition sequences that have the 
capability of binding to many different targets, creating a degree global regulatory 
control. 
The role of global regulation is important for the response and survival of cells 
in new and changing environments. These transitions require the rewiring of 
expression and simultaneous coordination of potentially hundreds of genes for a rapid 
and robust response to stimuli (e.g. nutrient availability, osmolarity, pH, and 
temperature (5, 8, 10-14)).  
In order to be an effective global regulator, an RNA or a protein needs to be 
able to recognize and differentiate the genes in their network from other genes. This 
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need is met through the use of a genetic barcode found that is recognized by their 
regulator. For RNA binding proteins, this barcode takes the form of a sequence motif 
that physically interacts with the protein (15). 
An identified motif can accelerate regulatory network characterization by 
informing the creation of a model to predict targets that interact with the protein. 
However, significant experimental effort is still required to find the true extent of the 
regulatory network. Additional effort is frequently required due to the fact that the 
context of the motif (i.e. secondary structure, position of motif in respect to promoter 
or untranslated region, etc.) holds importance to the degree of regulation and the 
effectiveness of the model to make accurate predictions. 
1.2 THE CARBON STORAGE REGULATOR: A GLOBAL RNP REGULATOR 
One regulatory system of particular interest that relies on RNA-protein 
interactions is the Carbon storage regulator (Csr) system from Escherichia coli. This 
widely conserved global regulatory system exhibits control over hundreds of genes 
through an interaction based on a simple RNA motif (16). In E. coli, there are four 
important components of the Csr system: two proteins, CsrA and CsrD, and two sRNAs, 
CsrB and CsrC (17-19). The central component of the system is the CsrA protein. CsrA 
has an important role in cellular regulation, as it has been proven to be conditionally 
essential in cells grown in glycolytic media (20). The CsrA protein is composed of only 
61 amino acids and forms a homodimer capable of binding RNA, specifically mRNAs. 
The interaction between the CsrA protein and a target mRNA affects the translation 
activity or stability of the mRNA (21). CsrB and CsrC interfere with the CsrA-mRNA 
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interaction by binding CsrA and competing with the mRNAs for the available CsrA. The 
abundance of CsrB and CsrC is modulated by the protein CsrD which directs degradation 
of the sRNAs (19, 22-28).  
CsrA recognizes its RNA targets through the nucleotide motif GGA (29). The 
GGA motif was first identified by its repetitive presence in CsrB  (30). Specifically, 
SELEX studies have shown that CsrA preferentially binds to AAGGA motifs or ANGGA 
motifs located in the loop of a hairpin (29, 31, 32). While the hexaloop structure is the 
preferred binding site of CsrA, NMR studies of RsmE, a closely related homologue of 
CsrA in Pseudomonas aeruginosa, have physically described the interactions between 
RsmE and lower preference variants of the GGA motifs and demonstrated that the hairpin 
structure is not necessary for the interaction (33). Furthermore, CsrA is capable of 
binding to two RNA sites and favors binding sites with a minimum distance of 10 
nucleotides between them (32).  
Interestingly, CsrA does not appear to have any catalytic activity, and the only 
purpose of CsrA is to bind to RNA. Characterizations of mRNA-CsrA interactions have 
revealed the mechanism that CsrA uses to regulate mRNA activity. Early observations of 
CsrA binding to mRNAs found that CsrA predominantly bound to GGA motifs in the 5’ 
UTRs of transcripts (19, 34). More extensive RNA footprinting of CsrA targets, such as 
glgC, pgaA, sdiA, cstA, and hfq (19, 34-37), have shown that CsrA binds multiple 
locations near the ribosome binding site of the mRNA. Considering that the CsrA 
recognition sequence, GGA, is similar to the Shine-Delgarno sequence, it is clear that 
CsrA functions by binding the mRNA to prevent the ribosome from binding.  
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While the most common mechanism of CsrA regulation is by interfering with 
ribosome binding, CsrA also utilizes other unique mechanisms to control expression of 
its targets. CsrA binding has been shown to inhibit gene expression by altering the 
structure of the mRNA so it becomes susceptible to RNAse degradation (34). Conversely, 
CsrA has been known to activate translation by altering the mRNA structure to favor 
ribosome binding (38) or to block rho utilization sites and stabilize the mRNA (39). CsrA 
interactions have also been shown to rely on post-transcriptional modifications (40). 
Interestingly, CsrA binding site analysis has suggested that CsrA can bind to any region 
of an mRNA (41), but all of the currently understood mechanisms of CsrA regulation 
require CsrA binding in the 5’UTR or near the translation initiation. 
With such a simple mechanism at the core of CsrA inhibition, the important 
question concerning CsrA is how it is capable of preferentially binding and regulating 
specific mRNA targets when the Shine-Delgarno is so similar to the CsrA site. One 
suggestion is that CsrA’s two RNA binding sites act cooperatively; one high affinity 
RNA site attracts CsrA so that the other binding site will be attracted to the RBS (32). 
However, this model is likely incomplete; the CsrA targets hfq and ycdT contain only a 
single GGA motif (36, 42). The mechanism that CsrA employs to preferentially bind 
these targets is not yet clear and raises concerns over the extent that CsrA regulates all 
mRNAs. 
Several experimental studies have been performed to measure the impact of CsrA 
on cellular pathways in E. coli. In these studies, genes impacted by the Csr system were 
identified using CsrA pulldowns (41, 43), microarrays (42), proteomics (21), C13 flux 
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analysis (44), and transcriptomic analysis of mRNA degradation patterns (45). 
Combined, these studies suggest that CsrA has an effect on 200-800 genes. That estimate 
indicates a large degree of uncertainty and calls into question whether CsrA interacts with 
these genes directly through the mRNAs or has a broader and indirect effect on these 
genes. 
Several efforts have been made to predict targets of CsrA by searching the 
genome for GGA motif variants. The first attempt to predict CsrA targets searched the 
genome for 3 degenerate versions of motifs containing GGA found  within a 25 
nucleotide window of the translation initiation site for all E. coli genes (21). This method 
predicted about 700 mRNAs as potential targets of CsrA. An alternative prediction model 
identified targets based on the number of GGA motifs present in 5’UTR (46). A positive 
prediction of a CsrA target required that multiple GGA sites be within 60 nucleotides of 
each other and present within the 5’ UTR of a gene CsrA target. These constraints 
identified approximately 160 potential targets in E. coli (46). These two sets of 
predictions vary widely in both the number and identity of the targets that they predicted. 
Different interpretations of the CsrA binding interaction will significantly impact 
computational predictions of mRNA targets.    
With the ambiguity in omics based measurements and predictive models, there 
has been slow progress in identifying the true, direct targets of CsrA. Considering the 
high number of potential CsrA-mRNA relationships, only about 17 targets have been 
well characterized experimentally in the literature. To rectify the dearth of knowledge 
surrounding such an important regulator, this work focused on developing methods 
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and models to better understand the nature of the RNA-protein interactions of the Csr 
system.  
1.3 EXPERIMENTAL CHARACTERIZATION OF RNA-PROTEIN INTERACTIONS 
The identification of an sRNA’s protein target has been a difficult task, as 
typical detection of interacting sRNA-protein pairs often requires extensive 
experimental characterization (47). Indeed, only two examples of regulatory 
sRNA-protein interactions have been identified and extensively characterized in 
bacteria: the Csr system (24, 25) and the 6S RNA (48). However, recent advancements 
in RNA sequencing technologies have made largescale discovery type of experiments 
more approachable (49).  
One of the major techniques for the largescale characterization of RNP 
interactions is cross-linking and immunoprecipitation (CLIP) (50). In CLIP 
procedures, cells are subjected to cross linking conditions (such as formaldehyde or 
UV light) to covalently link RNAs to proteins. The RNA-protein complex (RNP) of 
interest is purified from cell lysate using immunoprecipitation techniques, and the 
bound RNAs are identified using RNA-seq technologies. While variations on CLIP 
technologies have sought to improve the specificity of target interactions and identify 
exact binding sequences (41, 51), CLIP technologies are often criticized for being too 
promiscuous and identifying superfluous RNA-protein interactions or for requiring too 
high of an affinity of the RNA-protein interaction for accurate detection (52). 
 In addition to the limitations in identifying sRNA-protein interactions, current 
methods for studying and characterizing RNA-protein interactions are largely limited 
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to in vitro studies such as gel mobility shift assays (53), SELEX (54), electron 
microscopy (55), X-ray diffraction, and SAXS (56). While these tools are highly 
valuable, they fail to capture the complex natural roles RNPs play within their native 
cellular context.  
Current technologies available to study RNP interactions in vivo largely focus 
around fluorescence based techniques. Three common techniques are FRET, Yeast 
Three Hybrid systems, and fluorescence complementation techniques. FRET stands 
for Fluorescence Resonance Energy Transfer and is a common technique used to 
demonstrate when two molecules are in close proximity to each other. The concept 
behind FRET is that a fluorescence signal is produced when two fluorophores are in 
close proximity and the excitation of one fluorophore excites the second fluorophore 
to emit a unique fluorescence signal (57). The need for fluorophores can make in vivo 
characterization difficult because additional chemical modification is required to 
covalently link a fluorophore to the molecule of interest. FRET has been applied using 
in vivo produced fluorescent proteins, but these systems have been limited to 
eukaryotic systems and evaluation of protein-protein interactions (58).  
The Three Hybrid Systems creates a fluorescence signal by using an 
RNA-protein interaction to initiate transcription of a fluorescent protein (59). This 
system employs three fusion molecules to detect the interaction between the protein 
and RNA of interest. The protein of interest is fused to a transcription factor, and the 
RNA of interest is fused to a protein binding motif. A third party protein fusion 
consisting of a DNA binding protein and an RNA binding protein tethers the RNA to 
 8 
the DNA through the interaction of the RNA binding protein and the protein binding 
motif on the RNA fusion. When the protein of interest binds to the RNA of interest, 
the transcription factor is directed to the DNA to transcribe the signal for a fluorescent 
protein.  While this system does provide a relatively easy to use detection method, this 
system has only been applied in yeast and is not suited for prokaryotic systems. 
Additionally, this system relies upon tethering the RNA to the DNA, which can 
remove the functional context of the RNA-protein interaction of interest.  
The final fluorescence technique discussed here is the complementation assay. 
In a standard complementation assay, a fluorescent protein is divided into two 
fragments expressed as chimeric fusions to two separate proteins; this set up produces 
a fluorescence signal when the two proteins come into close proximity to allow 
refolding of the fluorescent protein fragments (60). Although the most common 
complementation assay examines protein-protein interactions in a technique described 
as Bi-molecular Fluorescence Complementation (BiFC), split protein 
complementation has been used to visualize mRNAs in bacterial and eukaryotic 
systems by tethering multiple fluorescent protein fragments to the RNA of interest by 
including the recognition sequences of well-known RNA binding proteins (61-63). 
This strategy of using third party RNA-protein interactions was referred to as Tri-
molecular Fluorescence Complementation (TriFC) when it was first implemented to 
detect and characterize mRNA-protein interactions in mammalian cells (64). Even 
though this strategy can be negatively influenced by the interaction assuming an 
orientation that is unfavorable for the refolding of the fluorescent protein, this 
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technique is popular because it can be implemented easily using plasmid based 
expression systems. Since TriFC has been demonstrated in prokaryotes, does not 
require extensive chemical modification to the molecules of interest, and can be 
created using a plasmid system, TriFC is well suited for studying the RNA-protein 
interactions of the Csr system in vivo.  
1.4 MODEL CHARACTERIZATION OF RNA-PROTEIN INTERACTIONS 
Physical characterization may be the first step in understanding any regulatory 
interaction, but modern biology looks to improve the understanding of regulation by 
developing computational tools to model and predict cellular regulation. One of the great 
challenges in modern biology is to understand the extent that any particular regulatory 
interaction has on the phenotype of a cell.  In order to achieve this task, research has 
focused on using computational methods to predict the genetic targets of regulatory 
proteins and RNAs. Currently, there is significant interest being paid to archiving omics 
data and model based predictions of regulatory interactions (65) with the hope that a 
more complete understanding of regulation can help develop better models to predict 
transcriptional outcomes (66). While identification of mRNA targets of sRNAs has been 
aided by genetic and bioinformatics analyses built around the understanding of nucleotide 
base pair interactions (67), there are no such generalizable models to predict 
DNA-protein or RNA-protein interactions. There are models being developed that 
attempt to predict RNA-protein behavior based on principles of atomic structure (68, 69), 
but these models can be difficult to implement because they require knowledge of the 
protein crystal structure. In general, predictive and mechanistic models of 
nucleotide-protein interactions are exceptionally limited and require experimental 
verification of the protein’s binding motif or consensus sequence. 
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While a variety of free energy models have been developed to describe 
transcription factors binding to DNA (70-72), free energy interpretations of RNA-protein 
interactions are typically quite rare. This discrepancy in model availability is largely 
related to the historical focus on transcription initiation and the general underappreciation 
of post-transcriptional regulation. Fortunately, the principles used to make DNA-protein 
interaction models can be applied to RNA-protein interactions. 
For DNA binding proteins, typical model development requires the identification 
of a consensus binding motif which is typically used to develop a position weight matrix 
or a free energy of binding model.  Simple models rely on the sequence similarity to the 
recognized motif in order to make a prediction on whether a sequence is a target of a 
protein, but more advanced models can use the sequence similarity to predict the affinity 
that the sequence has with the protein. These more advanced models require a reliable 
position weight matrix or free energy model that accounts for a nucleotide’s individual 
contribution to the binding interaction. The estimation a nucleotide’s individual 
contribution requires either experimental data, such as SELEX and other mutational 
studies, or predictions using Molecular Dynamics simulations (73). While developing an 
accurate model for nucleotide-protein interactions requires extensive characterization, a 
reliable model greatly aids the development of regulatory network models by identifying 
uncharacterized and unrecognized interactions that would otherwise be missed through 
experimental techniques.     
1.5 SUMMARY OF RESEARCH OBJECTIVES AND ACCOMPLISHMENTS 
Characterization of the CsrA-RNA interaction through experimental and model 
based techniques is an interesting technical challenge due to the overall number and 
complexity of the interactions. For example, the protein CsrA forms a dimer to bind 
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RNA at two binding interfaces; CsrB, for its part, is known to bind approximately nine 
CsrA dimers (30). This redundancy in binding sites suggests that molecular geometry 
plays a critical role in CsrA-RNA recognition. There is also a redundant sRNA (CsrC) 
that appears to duplicate CsrB function. Finally, CsrA is suspected to interact with 
hundreds of mRNAs. All of this suggests that CsrA is highly tuned to elicit various 
modes of regulation specific to the conditions of the cell.  
In order to better understand CsrA-RNA interactions, this work develops two 
fluorescence based assays to study CsrA interactions. One assay detects the interaction 
of the RNA with CsrA, and the other assay provides evidence of the regulatory effect 
of the interactions. Additionally, this work creates a model to predict the likelihood of 
CsrA regulating a specific mRNA.  
Chapter 2 of this dissertation describes efforts to create an in vivo reporter of 
RNA-protein interactions using a fluorescence complementation assay. Specifically, we 
developed the Tri-molecular Fluorescence Complementation assay (TriFC, Section 1.3) 
to detect the interaction of the protein, CsrA, and its regulatory sRNA, CsrB. In this 
assay, the protein CsrA was fused to the N-terminal segment of YFP. To direct the 
C-terminal domain to CsrB, CsrB was modified to include the binding sites of the 
well-documented RNA binding protein of the MS2 bacteriophage coat protein. The 
C-terminal complement of YFP is fused to the MS2 coat protein. When the two protein 
fusions bind to the modified CsrB RNA, we observed a fluorescence signal. The chapter 
discusses the practical design efforts that went into creating the fusion molecules. 
Importantly, we showed the ability of this fluorescence-based system to capture a range 
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of interactions from CsrA mutants that display differential affinity to an RNA target 
(74).  This quantitative nature to a three partite complementation assay had previously not 
been demonstrated in the context of detecting regulatory sRNA-protein interactions. This 
work also served as the basis for an assay to detect specific mRNA-CsrA interactions 
(discussed in Chapter 3). 
In Chapter 3, we investigated the interaction that CsrA has with 241 different 
mRNA targets using a translation assay. The 241 potential targets were selected using 
information from transcriptomics, proteomics, and CsrA co-purification assays. This 
translational fusion assay yielded a fluorescence signal that was related to the stability 
and translational activity of the mRNA targeted. In this system, CsrA concentration was 
modified through an inducible promoter, and variations in the fluorescence output were 
used as evidence of CsrA acting on the tested mRNA. Target mRNAs that displayed 
strong translation dependence to CsrA were evaluated using TriFC to detect the direct 
interaction between CsrA and the mRNA. With the two assays, we identified 19 
previously unrecognized targets of CsrA regulation. 
Chapter 4 discusses the creation of a CsrA-RNA binding model that predicts the 
effects of CsrA binding on translation. The effort to model CsrA targets used sequence 
information to generate a free energy based model to predict the affinity CsrA has to 
specific sites on mRNA targets. The model evaluates the impact of potential binding sites 
by generating separate predictions for CsrA binding to a single site and for CsrA binding 
multiple sites in the mRNA. Beyond predicting CsrA binding, the model predicts the 
regulatory effect of the interaction. To predict CsrA regulation, the model uses the 
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predicted secondary structure of the mRNA bound by CsrA as an input into the RBS 
Calculator which generates an overall prediction of the translation rate. The model of 
CsrA-mRNA interactions fits well into the RBS Calculator, as the prediction of CsrA 
binding is similar to how the RBS Calculator uses sequence based information to model 
mRNA-ribosome interactions (75). The predictions of CsrA regulation was compared to 
data generated from the 5’UTR translation assay (Chapter 3) to determine the 
effectiveness of the model in predicting mRNA-CsrA regulation. Future application of 
the model will predict CsrA interactions over the entire genome.  
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Chapter 2 
Development of a Tri-molecular Fluorescent Complementation assay 
(TriFC) to detect regulatory RNA-protein interactions 
This work has been previously published*. I was the primary author on this publication. 
 
* Gelderman G, Sivakumar A, Lipp S, & Contreras L (2015) Adaptation of Tri-molecular 
fluorescence complementation allows assaying of regulatory Csr RNA-protein 
interactions in bacteria. Biotechnology and Bioengineering 112(2):365-375.  
2.1 INTRODUCTION 
 One of the most basic needs of any biological characterization is the ability to 
detect interacting molecules. While in vitro techniques, such as electro-magnetic shift 
assays, are powerful methods for biophysical characterization, they are often criticized as 
lacking the proper cellular context for the interaction. This is especially true for sRNA 
based interactions due to the fact that most in vitro characterizations of sRNA rely upon 
in vitro transcription to produce sufficient quantities of sRNA for the assay. The 
preparation technique thereby removes any post-transcriptional processing that would 
normally be carried out in cellular conditions. These in vitro assays can be hindered by 
the misfolding or insolubility of the biological molecules which necessitates time 
consuming optimizations of the reaction conditions. Furthermore, these reaction 
conditions can be so extreme that they produce molecular orientations not relevant to in 
vivo conditions (RNA folding is particularly sensitive to magnesium ion concentrations). 
For these reasons, researchers often prefer in vivo techniques to detect interactions 
between biological molecules. 
 To detect most biological interactions, it is often necessary to engineer a method 
to produce a measurable signal in response to the desired interaction. An ideal system for 
the detection of inter-molecular interactions in vivo would be minimally invasive to the 
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cell, require minimal external equipment or reagents, and allow the interaction of interest 
to occur within normal biological conditions. Common techniques for the detection and 
characterization of interactions are Fluorescence Resonance Energy Transfer (FRET) 
(57), two and three hybrid systems (59), and complementation assays (76) (Section 1.3).  
Since each of these techniques have their advantages and disadvantages, the 
context of the interaction under investigation is important. Our body of work is largely 
concerned with RNA-protein interactions for prokaryotic systems with specific focus on 
the interactions of CsrA, a global, post-transcriptional regulator known to bind many 
different RNA targets. FRET would not be an ideal system for RNA-protein interactions 
as it requires additional extracellular modification of the molecules of interest. Three 
Hybrid Systems shows potential to detect RNA-protein interactions, but this system has 
only been applied in yeast. Fortunately, molecular complementation has been 
demonstrated to function in prokaryotic systems and can be accomplished using low cost 
plasmid based cloning techniques.  
 In this study, the concepts of complementation assays are applied to detect the 
RNA-protein interaction of the protein CsrA and its sRNA, CsrB.  Other studies have 
proposed TriFC in prokaryotic organisms before, using the technique to track the RNA’s 
presence in the cells (61, 63, 77). Our work represents the first application of a 
complementation assay to study an RNA-protein interaction in a prokaryotic system.  
2.2 RESULTS 
2.2.1 An in vivo sRNA-protein Tri-molecular Fluorescence Complementation system 
to detect CsrB-CsrA interactions in E. coli  
The system to interrogate the CsrB-CsrA (sRNA-protein) interaction was 
adapted from the Tri-molecular Fluorescence Complementation (TriFC) RNA 
visualization model (64). This system employs three molecular fusions (two protein 
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fusions and an RNA hybrid molecule) to allow visualization of RNA-protein 
interactions via the refolding of two inactive fragments of the enhanced yellow 
fluorescent protein (YFP). In this scheme, YFP is split into two inactive fragments, the 
N-terminal domain of YFP (NYFP; amino acids 1-154) and the C-terminal domain 
(CYFP; amino acids 155-238). These two fragments reassemble into an active, 
fluorescent protein when brought into close proximity by the interaction of the RNA 
and protein molecules. In our version of this scheme (illustrated in Figure 2.1A), 
CYFP is expressed as a fusion with the MS2 bacteriophage coat protein (MS2-CYFP), 
and NYFP is expressed as a fusion with the CsrA regulatory protein (CsrA-NYFP). 
The protein MS2 binds RNA with a high affinity for a specific RNA hairpin that is 
referred to here as the MS2 binding domain (MS2bd) (78). The two protein fusions are 
brought into close proximity by an RNA hybrid molecule containing the RNA 
sequences that bind CsrA and the MS2 coat protein, (CsrB and MS2bd, respectively). 
Each of these constructs is under promotional control from a distinct lac promoter. 
The assumption is that the interaction of CsrA fusion and CsrB fusion results in a 
measurable change in fluorescence that is mediated by the MS2bd-MS2 interaction.  
To construct the MS2-CYFP fusion, the CYFP fragment was tethered to the 
dlFG variant of MS2 (79) using a previously developed linker (80). The construction 
of the CsrB-2MS2bd fusion was guided by applications of the MS2bd-MS2 
interactions used for ribonucleoprotein purifications (81, 82).  In these schemes, 
multiple repeats of MS2bd are used to attract the MS2 protein to RNA molecules. We 
expressed the MS2bd RNA as a series of two of the high affinity stem loops to create 
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the RNA segment called 2MS2bd. In addition, three of the previously mentioned 
segments were self-ligated to form a longer RNA tag containing six of the high 
affinity stem loops (6MS2bd). In this case, CsrB is expressed with either the 2MS2bd 
or 6MS2bd, both inserted at nucleotide 320 of CsrB. We reasoned that the native 
folding of the CsrB RNA would be less affected by the addition of a non-native 
sequence at the 3’ end due to known patterns of co-transcriptional folding prevalent 
for intracellular RNA. The position at nucleotide 320 was chosen because available 
CsrB structural data  predicted that the next structural element would be an intrinsic 
transcriptional terminator (30). Lastly, the CsrA-NYFP chimera was constructed using 
a flexible linker (3X(GGGGS)) to connect the CsrA and NYFP proteins. The linker 
sequence was intended to be long enough to overcome possible steric hindrance from 
the complex geometry of a CsrB-CsrA interaction that could prevent YFP refolding. 
The NYFP segment included a C-terminal FLAG epitope tag (DYKDDDDK) to allow 
for the assaying of protein expression. These three constructs were combined into two 
plasmids (Figure 2.1B) to reduce the metabolic burden of expressing three individual 
plasmids. The MS2-CYFP construct is expressed on the plasmid pMS2-CYFP, and the 
interacting RNA fusion and protein fusion of interest are both expressed from the 
plasmid pCsrA-NYFP+CsrB-MS2bd. For negative controls, plasmids were created 




Figure 2.1: Tri-molecular fluorescence complementation method for studying Csr 
regulation  
A. Illustrations of the non-fluorescent RNA and protein fusions (top) and fluorescent 
RNA-protein complex (bottom). The protein of interest, CsrA, is expressed as a 
protein fusion with the N-terminal domain of YFP (NYFP), yielding CsrA-NYFP. 
The C-terminal domain of YFP (CYFP) is expressed as a fusion to the MS2 
bacteriophage coat protein (MS2), yielding MS2-CYFP. The hybrid RNA 
molecule contains the RNA of interest, CsrB, and the binding domains for the 
MS2 coat protein, MS2bd, and is called CsrB-MS2bd. The interaction of all three 
molecules results in fluorescence, as the interaction between the target protein 
and sRNA (CsrA and CsrB) drives the complementary fragments of YFP (NYFP 
and CYFP) to reassemble (bottom). 
B. Depictions of the two plasmids that are used to encode the three fusion 
products necessary for fluorescent complementation. The protein and RNA 
of interest are expressed on the same plasmid, while the RNA tagging 
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molecule (MS2-CYFP) is expressed on its own plasmid. Each construct is 
under transcriptional control from a lac promoter. 
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2.2.2 The proteins and sRNA retain biological function when expressed as the 
constructed fusions 
We next verified the expression of the constructed RNA and protein fusions. 
As shown by the Western Blotting Analysis in Figure 2.2A, successful expression of 
the four proteins (two fusion proteins, CsrA-NYFP and MS2-CFYP, and two non-
interacting controls, NYFP and CYFP) was achieved from the constructed plasmids. 
Figure 2.2A confirms that the protein fusions are expressed at their predicted 
molecular weights (27.8 kDa for CsrA-NYFP, 25.3 kDa for MS2-CYFP, 21.0 kDA for 
NYFP, and 12.6 kDa for CYFP).  In addition, we were able to detect stable dimer 
formation from CsrA-NYFP and MS2-CYFP at higher protein loading concentrations 
(Figure 2.2C). This observation is consistent with CsrA and MS2 being functional, 
since both CsrA and MS2 are known to form dimers (reviewed (83)).  Also, an 
additional band appears when CsrA-NYFP and MS2-CYFP are co-expressed (as 
indicated by the dashed arrow in lane 3 of Figure 2.2C), suggesting that YFP is 
capable of refolding in the context of the fusion proteins.  It should be noted that the 
electrophoresis of these proteins was conducted under denaturing conditions, but we 
suspect that the mercaptoethanol used to denature the proteins was not active enough 
to completely disrupt dimer formation.     
In addition to testing the protein fusions, we needed to confirm that the RNA 
fusion was being expressed and was functional.  Given that the CsrB fusion has 
additional nucleotides from the 2MS2bd or the 6MS2bd that have their own unique 
secondary structure, the extra nucleotides could interfere with the native structure of 
CsrB and its ability to bind CsrA in vivo. Functional CsrB was confirmed in our 
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CsrB-2MS2bd fusion by visual observation of a glycogen accumulation phenotype 
previously reported in the literature when CsrB is overexpressed (17, 28, 84). Figure 
2.2B illustrates the effect of CsrB overexpression causing greater glycogen 
accumulation as visualized by the darker iodine staining in the cell pellet of the cells 
expressing CsrB (D) and CsrB-2MS2bd RNA (C) than in the cells expressing the 






Figure 2.2: Evidence of protein and RNA expression 
A. Western Blot Analysis: Left panel - Anti-FLAG Western Blotting analysis 
using total protein extracts from cells expressing the CsrA-NYFP and 
MS2-CYFP proteins (lane 1), the CsrA-NYFP and CYFP proteins (lane 
2), and the NYFP and MS2-CYFP proteins (lane 3). Protein size markers 
are given on the left. Note that only the CsrA-NYFP and NYFP fragments 
are tagged with the FLAG epitope. The NYFP protein is 21.0 kDA and is 
 23 
circled in lane 3. The CsrA-NYFP protein is 27.8 kDA and is marked by 
an arrow. Lower bands are likely degraded proteins. Right Panel - Anti-
GFP Western Blotting analysis using total protein extracts from cells 
expressing the CsrA-NYFP and MS2-CYFP proteins (lane 1), the CsrA-
NYFP and CYFP proteins (lane 2), and the MS2-CYFP and NYFP 
proteins (lane 3). Protein size markers are to the left. The protein MS2-
CYFP is 25.3 kDA and is marked by an arrow. CYFP is 12.6 kDA and is 
circled. The smaller bands are likely degraded proteins.  
B. Observation of CsrB phenotype in RNA fusions: These are cell pellets that 
have been stained with iodine to reveal glycogen accumulation. All cells 
were grown with the listed plasmid until stationary phase. A) 
pCsrA-NYFP + 2MS2bd expressed the CsrA-NYFP protein and the 
2MS2bd RNA species. B) pNYFP + 2MS2bd expressed the NYFP protein 
and the 2MS2bd RNA species. C) pNYFP+CsrB-2MS2bd expresses the 
NYFP protein and the CsrB-2MS2bd RNA species. D) pUC19-CsrB 
expresses the CsrB RNA. The iodine staining is visually darker for tube C 
and D, indicating that glycogen accumulated as a result of expression of 
functional CsrB regulation. 
C. Western blot visualization of protein dimers: Left panel – anti-GFP blot 
for detection of CYFP proteins. Lane 1 contains the MS2-CYFP protein 
only; a solid arrow indicates a second band roughly double the size of 
MS2-CYFP indicating a properly folded MS2 dimer. Lane 2 is only the 
CYFP protein and shows no alternate bands. Lane 3 is protein extract 
from cells producing MS2-CYFP and CsrA-NYFP. A dashed arrow 
indicates the expression of a protein product larger than the MS2 dimer 
that likely corresponds to refolded YFP protein. Right panel – anti-FLAG 
blot for detection of NYFP protein. Lane 1 contains the NYFP protein. 
Lane 2 contains the CsrA-NYFP protein. Solid arrows indicate higher 
order products that correlate to proper CsrA dimerization. Lane 3 contains 
the proteins CsrA-NYFP and MS2-CYFP. A dashed line indicates the new 




  In addition to glycogen accumulation, we consistently observed cell adhesion 
to the walls of the culture vessel when CsrB-6MS2bd, CsrB-2MS2bd, or unaltered 
CsrB RNA was expressed, but no adhesion occurred in the controls expressing 
6MS2bd or 2MS2bd RNA. The formation of biofilm is a known phenotype of E. coli 
overexpressing CsrB (85). This evidence confirmed that the 3’ MS2bd tag did not 
completely interfere with the regulatory function of CsrB.  
2.2.3 The CsrB-CsrA interactions enhance total fluorescence from fluorescence 
complementation 
After confirming functional expression of all constructed fusions in vivo, we 
tested YFP refolding (as detected by fluorescence) under conditions that allowed or 
disallowed CsrB-CsrA interactions.  To ensure that a fluorescent signal was only 
obtained in the presence of both CsrA and CsrB interacting components, various 
isogeneic control systems were constructed where one or more of the fusions lacked 
CsrA, CsrB, or the MS2 protein.  For these experiments, combinations of the two 
plasmids carrying various forms of the genetic fusions were co-transformed into a 
mutant strain of E. coli, carrying a genomic knockout of the csrB gene (ΔcsrB::camR 
(25), a gift from Dr. Tony Romeo). It should be noted that CsrC, a complementary 
sRNA to CsrB, was still expressed in the cell and could potentially interfere with 
CsrB. However, CsrC has a much lower affinity for CsrA than CsrB (18) and is 
expressed at lower concentrations than CsrB (86), so the CsrB fusion RNA should 
preferentially bind RNA before CsrC.  
 25 
Cells were grown to stationary phase and the fluorescence of the cell 
population was measured using flow cytometry. As shown in Figure 2.3, fluorescence 
is enhanced only when the full system was expressed (curve a). Only modest shifts in 
fluorescence are observed in any of the controls where the sequence for CsrA, CsrB, 




Figure 2.3 Fluorescence complementation occurs in the presence of the three fusion 
molecules 
Each curve represents the population fluorescence for one of the system 
controls. a) Red solid line: Full system (CsrA-NYFP, CsrB-2MS2bd, and 
MS2-CYFP). b) Orange dotted line: No CsrB sequence control (CsrA-NYFP, 
2MS2bd, and MS2-CYFP). c) Blue dashed line: No CsrA sequence control 
(NYFP, CsrB-2MS2bd, and MS2-CYFP). d) Green long-dashed line: No MS2 
sequence control (CsrA-NYFP, CsrB-2MS2bd, and CYFP). The chart below 
summarizes the fusions present in each system and gives the numerical value 
of relevant fluorescence statistics. These experiments were done in a 






In order to quantitatively compare changes to fluorescence, we analyzed the 
difference in populations with the probability binning statistical method that is 
available in the FlowJo software (87). Probability binning is a modified chi-squared 
statistic that compares two univariate distributions. Probability binning is a preferable 
method to compare populations of exponentially distributed data as the method is not 
sensitive to the large variation in the standard deviation that occurs in more fluorescent 
populations.  In this method, the control population distribution is divided into bins so 
that each bin has the same number of events. These bins are then compared to sample 
distributions to calculate a chi-squared value, T(χ), which represents the number of 
standard deviations that the observed chi-squared value differs from the minimal 
meaningful value. This value is analogous to a t-score, and a T(χ) value greater than 
four predicts that two populations are different with 99% confidence. More 
importantly, this value can also be used to rank samples according to their similarity to 
a control population. Using this method to compare histograms, the T(χ) value has 
been calculated using the lowest fluorescent system, the no MS2 control (curve d), as 
the control population; these values are given in Figure 2.3. As expected, this analysis 
shows a significant shift in the fluorescence distribution when the fluorescence 
recombination is directed by the CsrB-CsrA interaction.  
The importance of using the CsrB knockout was tested by measuring the 
ability of the CsrB-CsrA interactions to direct fluorescence complementation in the 
wild type E. coli (MG1655), where native CsrB is present. As shown in Figure 2.4A, a 
significant shift in fluorescence is not detected with expression of the full system in 
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the wild type strain (in contrast to when the full system is expressed in the 
ΔcsrB::camR mutant strain, as seen in Figure 2.3). An explanation for this observation 
is that native CsrB outcompeted the designed CsrB fusion for CsrA-NYFP. This 
explanation is supported by the comparative Northern Blotting analysis of CsrB 
expression (Figure 2.4B). In this blot, the CsrB fusion was expressed in the wild type 
strain and the ΔcsrB::camR mutant strain. The blot shows the native CsrB is much 




Figure 2.4: TriFC is not observable in wt MG1655 cells 
A. Histograms and fluorescence statistics of TriFC system in MG1655. 
When all necessary proteins and RNAs for fluorescence 
complementation (population a, solid red) are present in MG1655, the 
observed fluorescence is lower than the control lacking the CsrB-
2MS2bd RNA (population b, dashed orange line) or the control lacking 
the full protein fusion CsrA-NYFP (population c, dotted blue line) 
B. Northern blot of expression of native and fusion CsrB. Lane 1 - 
MG1655 cells expressing a CsrB-6MS2bd variant of the fusion RNA. 
Lane 2 - RNA from MG1655 expressing a MS2 binding domain. Lane 
3 - ΔcsrB::camR mutant strain expressing CsrB-6MS2bd variant of 
fusion. The star symbol marks native CsrB RNA, and the arrow marks 
CsrB-6MS2bd RNA.  
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2.2.4 The sequence of the RNA binding domain affects the ability of the CsrB fusion 
to enhance fluorescence 
We next attempted to enhance the fluorescence signal by increasing the 
number of MS2 binding sites in the original RNA molecular design. Our rationale was 
that a higher number of binding sites would recruit more MS2-CYFP fragments to the 
RNA fusion and provide a better chance for fluorescence complementation to occur. 
This rationale is supported by in the literature where mammalian mRNAs have been 
tagged with up to 24 MS2bd repeats for effective visualization (88). Likewise, higher 
numbers of the hairpin repeats have been reportedly used to purify RNAs and RNPs 
(81). 
For our system, another RNA construct was made expressing a set of six MS2 
hairpins (6MS2bd) and was compared to the 2MS2bd RNA. Surprisingly, the 6MS2bd 
construct was unable to produce fluorescence complementation as a fusion with CsrB 
(Figure 2.5A).  
In contrast, fluorescence complementation was only observed with the 
2MS2bd system (discussed above). For comparison purposes, the T(χ) value of 
CsrB-6MS2bd and the 6MS2bd fluorescent populations (curves b and c) were 
calculated using the 2MS2bd population (curve d) as a control. These T(χ) values are 
much closer to each other than to the CsrB-2MS2bd population (curve a) (it should be 
noted that fluorescence values were measured on a different model cytometer than the 
curves presented in Figure 2.3).    
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Figure 2.5: Comparison of two variations of the MS2bd RNA sequence 
A. Fluorescence of cells expressing the 2MS2bd RNA fusion and the 6MS2bd RNA 
fusions in ΔcsrB::camR: a) Red solid line: Full system with CsrB-2MS2bd. Cells 
express CsrA-NYFP, MS2-CYFP, and CsrB-2MS2bd fusions. b) Green long-
dashed line: Full system with CsrB-6MS2bd. Cells express CsrA-NYFP, MS2-
CYFP, and CsrB-6MS2bd fusions. c) Blue dotted line: 6MS2bd control. Cells 
express CsrA-NYFP, MS2-CYFP, and 6MS2bd fusions. d) Orange dashed lines: 
2MS2bd control. Cells express CsrA-NYFP, MS2-CYFP, and 2MS2bd fusions. 
The full system with CsrB-2MS2bd (line a) shows a positive shift in fluorescence, 
while the full system with CsrB-6MS2bd (line b) is roughly equivalent to the no 
CsrB fusion RNA controls for the 2MS2bd and the 6MS2bd (lines c and d). The 
fluorescence values were taken using a FACSCalibur (BD Biosciences).  
B. Northern Blot analysis of the CsrB-2MS2bd (lane 1) and CsrB-6MS2bd 
(lane 2) RNA fusions in ΔcsrB::camR. Samples from total RNA extracts 
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(normalized to the same amount of RNA in each case) were probed for 
CsrB (see Methods). The * denotes the expected full length of the 
CsrB-2MS2bd or CsrB-6MS2bd RNA transcript (580 or 750 nucleotides, 
respectively). Both transcripts appear to have transcriptional termination 
very near the transition between the CsrB and the MS2bd at roughly 330 
nucleotides (marked with a **). In addition, both transcripts appear to have 
transcriptional terminators in the same locations for the next three bands 




To further understand why the 6MS2bd failed to enhance fluorescence, the 
6MS2bd and 2MS2bd constructs were analyzed by Northern Blotting analysis using a 
CsrB probe. As shown in Figure 2.5B, both fusions show premature transcriptional 
termination. It is expected that the full length CsrB-2MS2bd (lane 1) should be 580 
nucleotides and CsrB-6MS2bd (lane 2) should be 750 nucleotides. These shortened 
transcripts are likely the result of transcriptional termination, as we only observed 
these sharp bands for RNA lengths corresponding to the beginning of the MS2bd of 
the RNA fusion (at lengths longer than 320 nucleotides). While the banding patterns 
of both RNA transcripts are similar, the CsrB-2MS2bd shows a significant change in 
banding patterns near the end of its sequence when compared to CsrB-6MS2bd.  An 
interpretation of these observations is that CsrB-2MS2bd has a more beneficial 
conformation than the CsrB-6MS2bd for binding either the MS2-CYFP or 
CsrA-NYFP fusions to direct fluorescence complementation. It is possible that a 
higher number of MS2bd repeats may not be the optimal tag for a regulatory RNA that 
is expected to require high structural flexibility, rapid configuration changes, and the 
ability to sequester a high number of proteins (as in the case of the CsrB). In addition, 
it appears that the tagging of RNAs with a high number of repeated genetic 
palindromes (such as the multiple MS2bd sequences and the repeated cloning sites) 
leads to multiple conformations that are transcriptionally unstable or less likely to bind 
the MS2 target. Overall, these results are counterintuitive to our expectations that 
more binding sites would enhance the fluorescence values. 
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2.2.5 TriFC can detect a dynamic range of RNA-protein interactions 
To investigate the sensitivity of the fluorescence response of this system to the 
CsrB-CsrA interaction, several CsrA mutants were constructed with altered affinity to 
the target CsrB RNA.  The mutants of CsrA that were examined were V40A, V42A, 
and R44A (where the Kd for the association exhibits increases of 60-fold, 120-fold, 
and 150-fold, respectively, compared to wild type); these mutations were designed 
based on available in vitro biochemical characterization of this system (74). It is worth 
noting that these Kd values can only be used as qualitative comparative trends between 
the mutants since they were previously determined in vitro by gel-shift assays between 
CsrA and a single SELEX-optimized RNA hairpin motif.  As shown in Figure 2.6, 
these mutants displayed a pattern of fluorescence intensity in vivo that reflects 




Figure 2.6: Relative fluorescence values from mutants of CsrA expressed in the CsrA-
NYFP fusion 
Fluorescence distribution of TriFC system with mutations to the CsrA 
portion of the CsrA-NYFP fusion protein a) Red solid line: wt CsrA, b) 
Blue dotted line: V40A, c) Orange dashed line: V42A, and d) Green 
long-dashed line: R44A.  
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The least detrimental mutation to RNA binding affinity, V40A, yields almost 
no change in fluorescence. The next most detrimental mutation, V42A, modestly 
reduced fluorescence, and the most detrimental mutation, R44A, significantly reduced 
fluorescence to levels similar to the no interaction controls (data not shown). Using the 
R44A distribution as a reference, the T(χ) value reflects the increasing fluorescence of 
the population distributions (it should be noted that the T(χ) value depends on the size 
of the population as well, so the T(χ) of V40A is not directly comparable to the wt 
CsrA). Collectively, these observations are significant as they quantitatively correlate 
RNA-protein binding affinities to fluorescence readouts from this system.  
Importantly, this dynamic detection range confirms this system’s ability to capture a 
range of interaction affinities between CsrB and CsrA in E. coli. This type of 
quantitative nature to a three partite complementation assay had not yet been 
demonstrated in the context of regulatory sRNA-protein interactions in bacterial 
systems. Although the in vitro data predicts that all mutants would exhibit 
fluorescence changes relative to the wild type CsrA, it is possible that the presence of 
CsrA heterodimers in our study (where one CsrA is natively-encoded and the other is 
a mutant plasmid-encoded NYFP fusion) mitigates the negative effect of the mutation 
on CsrB-CsrA binding affinity (32). Additionally, the mutants were characterized 
using single RNA hairpins; CsrB, with its multiple CsrA binding sites, may behave 
differently with these mutants.  
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2.3 DISCUSSION 
The adaptations to the TriFC method developed in this work present a valid 
technique to study RNA-protein interactions in vivo in bacteria. Previous works using 
this system focused on using TriFC as a method to study RNA-protein localization 
(64), RNA visualization (77), or RNA dynamics (89). We have demonstrated the 
potential of this system to quantitatively assay regulatory sRNA-protein interactions in 
the context of their native pathways through fluorescence complementation. The 
ability of this system to capture these regulatory interactions in the context of the Csr 
network is highly promising, given the unique challenges presented by the complex 
geometry of its interactions. First, in this system, fluorescence complementation 
depends on the ability of a tagged CsrB RNA (CsrB-2MS2bd) to bind its target, CsrA, 
while the CsrA is fused to a foreign protein (NYFP). Secondly, the fusion interaction 
is further complicated by the observation that the number (and presumably 
configuration) of the MS2bd can have significant impact on the RNA structure. Lastly, 
CsrB is known to bind multiple copies of CsrA, potentially making it more 
challenging for the CsrA-NYFP chimera to bind the MS2 tagged CsrB in a position 
favorable for YFP refolding. Even within this complex arrangement, directed 
fluorescence complementation can detect sRNA-protein interactions, and it should be 
possible to adapt this system for other RNA-protein pairs. In Chapter 3, this method is 
adapted to detect mRNA-CsrA interactions. 
The ability to discriminate between various CsrA mutants presents the 
possibility of probing mutant libraries of RNA-protein interactions in vivo. A natural 
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advantage of TriFC is its potential for high-throughput applications given the relative 
ease of using cytometry to screen large libraries of mutants based on their fluorescent 
values. It becomes possible to envision the rapid identification of mutations that affect 
the binding affinity. This evaluation would be instructive to understand the critical 
residues that dominate intermolecular interactions of regulatory RNAs and their 
protein targets in vivo. This technique would serve to compare binding affinities of 
RNA variants generated by in vitro SELEX techniques to their binding capabilities 
observed in vivo. Lastly, this tool presents the potential to quantitate how interactions 
among cellular regulators change from outside stimuli triggering global adaptation 
responses.  
2.4 METHODS 
2.4.1 Construction of the MS2-CYFP containing plasmid 
The plasmid pMS2-CYFP encodes for the MS2 coat protein fused to the 
C-terminal fragment of YFP (aa 155-238) by the linker developed by Hu et al. 2002 
(80). The MS2 coat protein contains the deletions that prevent capsid formation that 
occur in the wild type coat protein (79). The plasmid pMS2-CYFP was adapted from 
the plasmid pDMSD-Y2 previously used to detect fluorescence between the proteins 
DmsA and DmsD (90), which originates from the vector pKNT25 (Euromedex).  The 
MS2-CYFP protein sequence is inserted in between the HindIII and ClaI recognition 
sites of the vector backbone pKNT25. An alternative plasmid was constructed with 
only the CYFP sequence in this location to produce a no MS2 control. The MS2 coat 
protein and the plasmid pDMSD-Y2 were gifts from Dr. Matt DeLisa.  
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2.4.2 Construction of the CsrA-NYFP protein encoding plasmid 
The plasmid pCsrA-NYFP encodes for the CsrA polypeptide (17) fused to the 
N-terminal domain (amino acids 1-154) of YFP by a fifteen amino acid linker 
consisting of 3 repeats of GGGGS. This sequence was constructed with the plasmid 
pDMSA-Y1, which was a gift from Dr. Matt DeLisa (90). The NYFP protein contains 
a C-terminal FLAG tag in order to be detected by Western Blot. Standard cloning 
techniques were used to create this sequence. An alternative plasmid was constructed 
to create a no CsrA control, in which the linker-NYFP sequence was inserted into the 
pDMSA-Y1 plasmid to create the plasmid pNYFP. 
2.4.3 Construction of the RNA encoding fusion  
The RNA fusion construct was synthesized to express CsrB (30) and a 
sequence containing the MS2 binding domain (MS2bd) using the pUC19 vector. The 
CsrB sequence was a gift from Dr. Tony Romeo. The MS2 binding domain includes 
the high affinity MS2 coat protein binding domain (78, 82). This sequence was a gift 
from Dr. Marlene Belfort. There were two variants of the MS2bd used in this study. 
One variation of the MS2bd contains six of the high affinity hairpins (6MS2bd) and is 
a series of self-ligations of the sequence proposed by Bardwell and Wickens. The 
other variation contains only two of the hairpins (2MS2bd). The 2MS2bd was 
constructed after the 6MS2bd, and the process is described in the next section.  
The 6MS2bd was inserted into the CsrB RNA at position 320 of the CsrB 
sequence. This nucleotide was chosen to insert the MS2bd because it is upstream of 
the stem loop predicted to be part of the transcriptional terminator (30). In order to 
 40 
construct the RNA fusion in pUC19, the lac promoter was manipulated at the M13-rev 
sequence (5’-CAGGAAACAGCTATGACCATG) to include the NdeI cut site at the 
beginning of the pUC19 translation initiation site (5’-
CAGGAAACAGCATATGACCATG) using the Quick Change II Site Directed 
Mutagenesis kit (Agilent). The 6MS2bd was inserted into the pUC19 vector at the 
newly formed NdeI site and the AatII restriction site. The stop transcription site of 
CsrB was added to the 3’ end of the MS2bd. This created the 6MS2bd RNA sequence 
that would be used as a no CsrB control. The 5’ section of CsrB was then added to the 
5’ end of the 6MS2bd using the restriction sites of NdeI and KasI. (The KasI sites 
were part of the 6MS2bd.) This created the CsrB-6MS2bd RNA fusion. 
2.4.4 Construction of the two-promoter RNA and protein encoding plasmid and 
CsrA mutants 
To simplify expression of the three interacting elements (NYFP fusion, CYFP 
fusion, and RNA fusion), the CsrA-NYFP and CsrB-MS2bd fusions were combined in 
the same plasmid. This system was constructed by amplifying the CsrB-6MS2bd RNA 
fusion up stream of its lac promoter with the primers: 
5’-CCTGACGTCGCGAGGAAGCGG and 
5’-TTAGACGTCAATAAAAAAAGGGAGCAC. The amplified genetic material was 
digested with AatII and ligated into plasmid pCsrA-NYFP. This created the plasmid 
pCsrA-NYFP+CsrB-6MS2bd. This plasmid was modified with several mutations to 
include additional restriction sites to aid in the insertion of additional genetic 
sequences to the CsrA or the CsrB positions on the plasmids. A second version of this 
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plasmid was constructed to reduce the size of the RNA fusion by reducing the 
6MS2bd from six repeats of the MS2 hairpin (6MS2bd) to two repeats of the hairpin 
(2MS2bd). This was done by digesting the plasmid with KpnI and self-ligating the 
plasmid to create the plasmid pCsrA-NYFP+CsrB-2MS2bd. 
Several mutant varieties of CsrA were introduced into the CsrA-NYFP protein 
in the plasmid pCsrA-NYFP+CsrB-2MS2bd. The mutations to CsrA were V40A, 
V42A, and R44A, as these sites have been previously identified as important to CsrA 
function (74). These mutations were constructed using the protocols of the Quick 
Change II Site-Directed Mutagenesis kit (Agilent).  
Negative controls for this system were created by removing the CsrA, CsrB, 
MS2 genetic elements from these plasmids using standard cloning techniques. These 
plasmids are named for the proteins and RNAs that they express. For a list of plasmids 
created by this study see Table 2.1: Plasmids and Fusion Expression. 
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 Table 2.1: List of plasmids with protein and RNA fusion products used in this study   
Plasmid Protein Fusion RNA Fusion 
pCsrA-NYFP+CsrB-2MS2bd CsrA-NYFP CsrB-2MS2bd 
pCsrA-NYFP+CsrB-6MS2bd CsrA-NYFP CsrB-6MS2bd 
pCsrA-NYFP+2MS2bd CsrA-NYFP 2MS2bd 
pCsrA-NYFP+6MS2bd CsrA-NYFP 6MS2bd 
pNYFP+CsrB-2MS2bd NYFP CsrB-2MS2bd 
pNYFP+CsrB-6MS2bd NYFP CsrB-6MS2bd 
pMS2-CFYP MS2-CFYP - 
pCYFP CYFP - 
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2.4.5 Cell culture and expression of genetic fusions 
The strain RG1-B MG1655 (25), a gift from Dr. Tony Romeo, is a genomic 
knock out of CsrB and was selected for expression of all vectors in this study. The 
RG1-B MG1655 strain was transformed with plasmids sequentially using CaCl2 
transformation protocols. The first plasmid transformed into cells was the 
pMS2-CYFP or the pCYFP plasmid, respectively, and was followed by the 
CsrA-NYFP+CsrB-2MS2bd vector, or one of its variants. After cells were 
transformed with both plasmids, individual colonies were inoculated into shaker flasks 
containing 40 mL of Luria Broth (LB) augmented with the antibiotics kanamycin and 
ampicillin (to reflect the two plasmids carried by the cell). The cultures were grown at 
25ºC with agitation. All genetic fusions were under the control of the lac promoter. 
However, as the lac promoter is slightly leaky, the addition of inducer was not used to 
control expression. At least three different cell populations from each plasmid 
combination were grown for analysis by flow cytometry. 
2.4.6 Collection and analysis of fluorescence data 
Cells were analyzed by flow cytometry using the FACSAria III flow cytometer 
and the FACSCalibur (BD Biosciences). Cells were prepared for cytometry by 
diluting the cells into phosphate buffered saline (PBS: 137 mM sodium chloride, 2.7 
mM potassium chloride, and 10 mM phosphate buffer, pH 7.4-7.6) to a concentration 
on the order of 10
7
 cells/mL.  The cells were excited with the 488 nm laser found in 
the flow cytometer, and the cell population was determined from the forward scatter 
and side scatter distributions reported by the cytometer. Data was collected for at least 
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25,000-50,000 active cells. The high number of events collected ensures enough 
events to assume that the population distribution would be unaffected by rare events. 
For this study, all cells are analyzed during the population’s stationary phase.  
Analysis of the cytometry data was done using the FlowJo software (Tree Star, 
Inc.).  Examination of the fluorescence values showed that the forward scatter and side 
scatter of the true cell population overlapped with non-fluorescent background noise. 
In order to separate the fluorescent cellular population and non-fluorescent 
background signal, the events were plotted on a dot plot of the fluorescence covered 
by the FITC vs. PE band pass sensors of the cytometer. These two filters were selected 
because they cover the range of emission values of YFP fluorescence and are able to 
differentiate fluorescence due to YFP and the background level. From this 
comparison, it was determined that fluorescence from YFP could be differentiated 
from the background using the difference in the FITC-A fluorescence of the two 
populations. All events that were above the FITC-A fluorescence of the background 
noise were considered to be living cells and were compared using the PE-A reading to 
calculate the mean, geometric mean, median, mode, and standard deviation of 
fluorescence. These calculations were made by the FlowJo software. The histograms 
of fluorescence were normalized and presented using suggested parameters by FlowJo, 
which uses the mode of a reference population to calculate the scaling factor between 
populations.  
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2.4.7 Protein analysis - extraction and Western Blotting 
Soluble proteins were extracted from 10 mL of saturated cell culture that was 
grown as described in the Cell Culture and Expression of Genetic Fusions section 
(Section 2.4.5). The cells were collected by centrifugation and re-suspended in 1 mL 
of PBS in a 1.5 mL conical centrifuge tube. Cells were lysed by sonication with the 
Qsonica 55 probe (Qsonica, LLC). Cells were kept on ice and sonicated for 60 
seconds, maintaining between 10-15 W of output energy. The soluble portion of the 
cell lysate was quantified for total protein content using a Bradford assay 
(ThermoScientific) relative to standards of bovine serum albumin (New England 
Bioloabs). Electrophoresis was conducted using the Miniprotean (BioRad) 
electrophoresis set up. The wells were loaded with 5 µg of soluble protein diluted into 
40 µL with an appropriate amount of denaturing SDS sample loading buffer and 
heated to 95ºC for 5 min. The gel was an SDS-PAGE gel prepared with the Laemmli 
setup using a 12% resolving gel and a 6% stacking gel. Samples were run with the 
ColorPlus™ Prestained Protein Marker, Broad Range (NEB) as a standard. Gels were 
transferred to a nitrocellulose membrane using the TranBlot SD Semi-Dry 
Electrophoretic Transfer Cell (BioRad). Gels were prepared by soaking in Bjerrum 
and Schafer-Nielson transfer buffer with SDS for 10 min. The transfer was decided to 
be sufficient when the colored protein marker at 46 kDa was no longer visible in the 
gel. Blotting was done with standard procedures at room temperature on a rocking 
platform. The initial blocking step was conducted with 5% dry milk in Tris-buffered 
saline solution (TBS). The protein fusions of NYFP and CYFP were detected using 
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the Anti-FLAG M2 antibody (Agilent) and the Anti-GFP (Roche) as a primary 
antibody, respectively. Both antibodies were diluted to the manufacture specifications 
in TBS and 1% w/v dry milk. The secondary antibody used in both cases was the 
Anti-Mouse IgG (H+L), HRP Conjugate (Promega), diluted to the manufacturers 
specifications in TBS and 2% (w/v) dry milk. All images were developed using the 
Immun-Star™ HRP Chemiluminescent kit (BioRad) and the ChemiDoc™ MP 
Imaging System (BioRad).  
2.4.8 RNA analysis: RNA extraction and Northern Blotting 
RNA was extracted from cell pellets collected from 2 mL of saturated liquid 
culture using the TRIzol® (Life Technologies) RNA extraction reagent. Cells were 
lysed in the TRIzol reagent using silica beads and a bead beater to agitate cells for 100 
seconds. The RNA extraction followed the TRIzol instructions. RNA was quantified 
using absorbance at 260 nm detected by the NanoDrop™ Spectrophotometer (Thermo 
Scientific). Electrophoresis was conducted using the Protean II™ (BioRad) 
electrophoresis array and using 5% denaturing Urea-PAGE gels. 10 µg of total RNA 
was loaded into the gel. Radio labelled PhiX174 DNA/HaeIII Markers (Promega) 
were used as molecular weight standards. Radio labelling was conducted using gamma 
P32 ATP (Perkin Elmer) and T4 polynucleotide kinase (NEB).  Transfer was 
performed using a Hybond-N+ (GE Healthcare Life Sciences) nylon membrane and 
the Trans-Blot™ (BioRad) transfer system. The RNA was fixed to the membrane 
through UV crosslinking using the HL-2000 HybriLinker™ (UVP) system using the 
UV settings of 1200 µJ/cm2.  
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RNA membranes were blotted with the DNA probe “CsrB Probe 4”. The 
sequence of CsrB Probe 4 is 5’-CCGAATCATCCTGACCGG-3’ and binds the CsrB 
RNA between nucleotides 152-170 of CsrB. All probes were radiolabeled with P32 
using gamma P32 ATP (Perkin Elmer) and T4 polynucleotide kinase (NEB). Blotting 
was carried out by incubating crosslinked membranes with 20 pmol of radiolabeled 
DNA with 15 mL of hybridization buffer (Perfect Hyb™ Plus hybridization buffer 
(Sigma)) at 42ºC with rolling agitation for at least 1 hour. The membranes were then 
incubated with solutions of saline sodium citrate with 0.1% w/v SDS (1X SSC is 150 
mM sodium chloride, 15mM trisodium citrate, pH 7.0). The membrane was first 
incubated with 5X SSC for thirty minutes followed by two incubations thirty minute 
incubations with 1X SSC. The membranes were washed with distilled water until all 
SDS was removed.  The images of the membrane were taken using a phosphor screen 





 Translational assay for characterizing CsrA regulation on mRNA 
transcripts with interaction validation using TriFC 
3.1 INTRODUCTION 
The regulatory protein CsrA has been previously described as a global regulator 
of translation. As such, a better understanding of the targets regulated by this system is of 
vital importance to understanding cellular regulation. This knowledge could also improve 
genetic models of regulatory networks, which are often limited to transcriptional models 
(91, 92). Previous attempts to characterize CsrA’s “targetome” have focused on either the 
identification of mRNA-CsrA interactions using crosslinking and immunoprecipitation 
(CLIP) techniques or analyzed proteomic, transcriptomic, and metabolomic data of Csr 
modified systems (21). Although both techniques are powerful tools to characterize 
complex systems, they both fail to make definitive claims of regulatory interactions. 
CLIP is often criticized because the method identifies inconsequential reactions (50), and 
omics data is unable to identify direct interactions. Ideally, any attempt to characterize a 
regulatory system would showcase direct interactions and utilize the regulatory 
mechanism in order to demonstrate the capacity of the regulatory interaction. 
We have developed a translational based assay to characterize the effects of the 
presence of CsrA on specific mRNA targets. In our assay, an mRNA target of interest is 
modified to produce a translational fusion with GFP to provide a fluorescence signal that 
correlates to the translational activity of the mRNA target. We utilized a plasmid-based 
expression system to control the expression of CsrA. Changes in the fluorescence level in 
relation to CsrA expression indicate a regulatory interaction occurring between the 
mRNA and CsrA. Furthermore, this system ameliorated many of the issues caused by 
indirect regulatory interaction by moving the expression system to a plasmid based 
 49 
system. Approximately 250 mRNA targets were evaluated for their response to CsrA 
expression using this translational assay. These targets were largely identified from omics 
based studies of the Csr system that were done in collaboration with Steven Sowa 
(publication in review).  
These regulatory interactions identified in the translational assay were further 
characterized by adapting the TriFC method presented in Chapter 2 to detect specific 
mRNA-protein interactions. Taken together, the characterization of the physical 
regulatory response and the evidence for direct mRNA-CsrA interactions provide strong 
evidence for the identification of 19 targets of CsrA previously undocumented in the 
literature (Table 3.4). 
3.2 RESULTS 
3.2.1 The 5’ UTR translational assay  
We augmented a translational assay to assess the effect CsrA has on the 
translational activity of an mRNA target. In this system, the mRNA reporter consisted of 
the 5’ UTR of the mRNA of interest and 100 nucleotides of the coding sequence (CDS) 
attached in frame to a GFP reporter. The strength of translation from the targeted mRNA 
is related to the fluorescence intensity. It was decided that the translational reporter would 
test the 5’UTR and 100 nucleotides of the coding sequence based on the observation that 
most documented CsrA sites bind mRNA in the 5’UTR and near the translation initiation 
site to alter translational activity (41). 
Targets were examined for their fluorescence intensity in the presence and 
absence of excess CsrA to determine the effect that CsrA had on translation. A schematic 
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Figure 3.1: Schematic of 5’UTR translation assay with sample outcomes 
A. Concept of the 5’UTR translation assay: The system is composed of two 
elements, the inducible CsrA expression system, and a 5’UTR and CDS of a gene 
of interest. In this system, the mRNA of interest is produced constitutively. The 
mRNA target of interest translates a section of its own protein fused in frame to a 
GFP signal that is easily detectable by flow cytometry. Evaluation of the effects 
of CsrA on the test sequence compares the fluorescence output when CsrA is 
present to when it is not present.  
B. Sample data of the three observable outcomes of CsrA’s relationship to target 
mRNA translation: Left panel, CsrA expression increases observable 
fluorescence of population. Middle panel, CsrA expression does not affect 
















 The system adapts a translational assay from recent work  analyzing the kinetics 
of the Csr system (93). In that work, the authors created a translational fusion of the 
5’UTR and translational initiation site of glgC and GFP to understand how perturbations 
to the concentration of CsrA or CsrB affected the translation from glgC.  In this work, the 
5’UTR assay was developed from their plasmids pHL1756 and pHL600 and their 
modified E. coli strain, HL4142. All strains and plasmids are available from Addgene ® 
services.  
The plasmid pHL1756 contains a constitutively active promoter that is capable of 
producing a transcript that contains the 5’UTR of a selected mRNA and the coding 
sequence for GFP. In this study, we modified the segment of the plasmid containing the 
5’UTR sequence to investigate mRNA targets of interest. The plasmid pHL600 contains 
an inducible CsrA protein coding sequence that can be used to alter the concentration of 
CsrA. These plasmids were expressed in the strain HL4142, which contains genetic 
knockouts of the genes pgaA, glgC, csrA, csrB, csrC, and csrD. Removing these genes 
ensures that native expression of the Csr system doesn’t affect the inducible, plasmid 
based components. Removing pgaA prevents biofilm development that can occur in a Csr 
deficient strain. It is important to note that csrA has been described as essential in the 
past, but recent work has shown that cells can survive a knockout of csrA, provided that 
the gene glgC is also removed (20). 
3.2.2 Selection of mRNA targets 
Potential mRNA targets were selected using two sources: 1) experimental data 
from an omics study of Csr mutants that included CsrA co-purification assays and 2) 
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sequence based predictions of CsrA binding. The experimental data is from a work that 
was done in collaboration with Steven Sowa (in review). The model predictions are based 
on the presence of the relative number of GGA based CsrA binding motifs present in the 
5’UTR and the first 100 nucleotides of the coding sequence. Genes that had more than 3 
such motifs were selected to be analyzed by the translational assay. This method of 
predicting CsrA targeted mRNAs is similar to previously proposed methods (46). 
Additionally, several targets were evaluated that were not fully supported by omics 
predictions or predicted as CsrA binding sites. While some of these target sequences were 
included to provide a potential pool of negative controls, we found that many of these 
targets had ambiguous omics data that could suggest a potential relationship to Csr under 
less stringent statistical methods. Although the evidence for these specific targets was not 
strong enough to be established as a target in the analysis done in our collaboration, these 
targets would have a statistically higher rate of interactions with CsrA than a truly 
random pool of targets. This distinction is important for the model based characterization 
of these targets performed in Chapter 4. The rationale for selecting a target mRNA 
appears in Table 3.1. 
The mRNA sequences were designed with the shortest identifiable 5’UTR 
annotated by RegulonDB. In cases where genes had no designated transcriptional start 
sites or the gene was an internal gene in an operon, the 5’UTR was arbitrarily designated 
as 100 nucleotides preceding the translational start site.  
A complete list of the mRNAs and the sequences tested can be found in Appendix 
Table A.1. 
 54 
3.2.3 Selected targets display a wide range of reactions to CsrA 
241 targets were tested in the 5’ translational assay, of which 140 targets 
displayed measurable levels of GFP production that allowed us to evaluate their potential 
of being regulated by CsrA. The designed targets likely had a high failure rate due to the 
insolubility of the fusion protein produced. CsrA based repression or activation of targets 
was measured as the ratio of the background corrected average fluorescence output when 
CsrA was not induced (low levels of free CsrA) to the corrected fluorescence output 
when CsrA was induced (high levels of free CsrA). The background fluorescence was 
estimated as 3 fluorescence units (Section 3.4.2). Values greater than 1 indicate CsrA 
repression of the mRNA’s translational activity. Table 3.1 reports the fluorescence values 
of the two replicates for when CsrA was induced and not induced, the ratio of the average 
fluorescence values, and the method that identified the gene as a potential target. A * 
symbol next to the average ratio indicates targets that had significantly variable replicate 
values compared to the ratio. Table 3.2 reports the targets that did not have sufficient 
fluorescence activities for further analysis.  
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glgC 11.00   362.50   44.94   Omics data 
pckA 14.03 14.40 406.64 424.20 36.77   Omics data 
glsA 83.18 28.73 933.21 1086.62 19.01   Omics data 
aidB 32.27 40.71 563.78 575.95 16.93   Omics data 
rseA 29.27 25.54 234.95 338.07 11.62   Motif prediction 
maeB 13.90 14.30 109.01 146.14 11.22   Omics data 
thiG 31.85 30.02 300.21 324.27 11.07   Omics data 
yidQ 13.38 14.05 111.36 131.85 11.07   Motif prediction 
yafQ 163.23 166.02 1755.13 1644.69 10.5   Motif prediction 
mscS 12.39 12.09 79.66 111.60 10.02   Omics data 
uspG 27.41 27.13 217.64 231.74 9.13   Omics data 
deoD 23.76 21.96 145.77 214.89 8.93   Motif prediction 
uidR 27.87 22.40 214.70 180.95 8.8   Motif prediction 
acnA 9.05 8.99 44.30 56.89 7.91   Omics data 
ydhQ 75.48 78.80 614.70 517.68 7.6   Omics data 
frdB 126.54 117.65 887.13 895.14 7.46   Omics data 
rnk 39.88 32.98 251.76 250.67 7.42   Omics data 
hflK 82.82 90.03 546.82 690.03 7.38   Omics data 
astD 42.78 33.10 249.20 248.99 7.04   
Weak/no 
evidence 
poxB 7.82   35.72   6.79   Omics data 
nnr 50.25 109.46 390.51 638.23 6.65   
Weak/no 
evidence 
gshB 37.12 41.16 231.69 252.03 6.61   Motif prediction 
fucO 678.09   4203.25   6.22   Omics data 
moaB 45.94 42.39 231.33 254.66 5.83   Omics data 
gstA 10.5 15.5 60.78 59.76 5.73   Omics data 
ucpA 230.74 292.04 1434.58 1519.02 5.7   Omics data 
cysD 9.28 16.81 50.98 66.12 5.53   Motif prediction 
















rnr 191.22 219.62 954.43 1002.76 4.82   
Weak/no 
evidence 
hemX 99.27 85.28 387.8 477.01 4.81   Omics data 
ltaE 19.47 21.36 87.24 86.14 4.81   Omics data 
glpR 47.44 47.89 214.89 219.32 4.79   Omics data 
entF 11.59 12.07 43.24 45.43 4.68   Omics data 
gadA 31.25 36.99 149.00 139.34 4.54   Omics data 
ahr 127.33 130.72 606.55 484.99 4.31   Omics data 
tnaA 6.51 7.22 21.65 17.2 4.25   Motif prediction 
pgaA 10.56 12.46 34.51 42.17 4.15   Omics data 
hfq 10.74 11.15 33.22 36.7 4.02   Omics data 
entC 15.17 15.97 51.90 54.00 3.97   Omics data 
clpB 27.68 25.17 99.07 90.09 3.91   Omics data 
rpoS 31.00 31.78 107.54 115.92 3.83   Omics data 
uxaB 48.61 51.52 177.32 183.65 3.77   Omics data 
pgm 69.9 79.05 274.04 261.42 3.7   Omics data 
tauD 87.62 93.59 304.57 337.22 3.63   Omics data 
gadB 40.02 33.74 137.88 108.61 3.55   Omics data 
proP 12.56 13.12 37.98 37.71 3.54   Omics data 
dps 29.91 17.14 80.82 70.2 3.53   Omics data 
relA 34.79 29.82 99.39 106.93 3.42   Motif prediction 
icd 546.93 498.99 1756.53 1797.33 3.41   Motif prediction 
ydeP 33.43 39.12 110.65 112.03 3.26   Omics data 
evgA 9.00 9.44 24.37 21.64 3.22   Omics data 
gstB 7.55 13.26 13.37 39.44 3.16 * 
Weak/no 
evidence 
sdhA 17.56 14.14 47.31 38.72 3.11   Omics data 
groL 192.57 189.07 542.4 587.87 2.99   Omics data 
ydjA 647.22 773.12 1985.81 2244.20 2.99   Omics data 
rspB 7.32 6.90 13.60 16.51 2.93   
Weak/no 
evidence 
hemG 10.03 10.03 22.47 24.55 2.92   Omics data 
yfgM 6.34 5.86 11.53 12.43 2.9   Motif prediction 
nhaR 7.83 8.76 17.54 18.87 2.87   Omics data 















sdiA 10.75 12.16 23.85 27.59 2.69   Known target 
ybeL 89.81 82.98 162.32 280.18 2.62   Omics data 
ybaL 9.16 9.10 17.76 18.97 2.51   Omics data 
fdoH 7.13 7.28 12.87 13.71 2.45   Omics data 
elaB 57.74 55.77 137.33 131.34 2.44   Omics data 
crp 27.75 23.56 54.57 57.05 2.33   
Weak/no 
evidence 
cysJ 20.33 20.09 41.53 42.39 2.26   Omics data 
cstA 25.99 29.71 53.12 63.22 2.22   Omics data 
fabB 10.23 11.37 19.70 18.90 2.09   Motif prediction 
dkgA 694.31 1319.67 1997.46 2105.04 2.04   Omics data 
ppc 92.76 90.75 230.81 134.11 2.02 * Motif prediction 
pspA 33.41 32.25 62.98 63.50 2.02   Omics data 
yhiI 9.78 11.40 19.29 16.64 1.97   Omics data 
ahpC 1050.90 1884.68 2005.14 3731.33 1.96 * Motif prediction 
uxaA 67.36 61.08 117.37 125.22 1.93   Omics data 
sucB 9.11 75.74 9.13 146.83 1.9   Omics data 
ppk 20.01 20.82 37.50 33.98 1.88   Omics data 
sucC 1040.28 1023.12 1734.97 1998.94 1.81   Omics data 
yebE 627.76 619.18 1127.27 1100.09 1.79   Omics data 
truC 7.37 7.26 10.67 9.78 1.67   Omics data 
yaeP 15.49 14.54 22.31 23.21 1.64   Omics data 
glcB 213.39 199.86 312.71 359.68 1.64   Omics data 
dsrB 1287.09 1614.30 2242.49 2488.13 1.63   Omics data 
cysK 196.12 185.57 273.41 337.99 1.61   Motif prediction 
lsrF 563.76 639.45 914.99 1018.06 1.61   Omics data 
ycaC 16.52 10.43 21.63 17.36 1.57   Omics data 
iscS 179.04 238.30 363.66 279.00 1.55 * Omics data 
yecC 9.59 11.24 14.50 14.17 1.53   Omics data 
katG 1107.23 1114.86 1690.52 1621.26 1.49   
Weak/no 
evidence 
bfr 48.35 57.03 72.84 75.50 1.43   Omics data 
csiD 498.40 494.36 709.36 687.00 1.41   Omics data 















pepT 1499.42 1374.93 1894.61 2026.80 1.37   
Weak/no 
evidence 
groS 1174.81 1197.86 1551.13 1605.79 1.33   Omics data 
iscR 184.19 193.26 252.90 244.29 1.32   
Weak/no 
evidence 
dnaK 611.82 736.98 869.26 848.69 1.27 * Omics data 
flu 183.48 80.91 209.58 122.13 1.26 * Omics data 
sucA 11.61 11.93 14.07 13.63 1.24   Omics data 
aroG 229.99 216.58 285.83 257.30 1.22   Omics data 
fabI 221.46 244.60 252.91 305.51 1.2 * Motif prediction 
carB 45.68 49.39 54.71 54.20 1.16   Omics data 
yceD 45.53 37.81 46.22 47.64 1.14 * Omics data 
pntB 17.23 16.26 18.09 18.68 1.12 * Omics data 
proB 11.60 3.37 12.17 3.84 1.12 * 
Weak/no 
evidence 
fecA 42.75 38.93 44.06 45.31 1.10 * Negative Control 
hchA 520.13 482.02 529.41 560.37 1.09 * Omics data 
yjbD 12.94 14.79 14.82 14.79 1.09 * Omics data 
eno 28.58 26.97 29.60 29.80 1.08 * Omics data 
talA 1133.88 1247.33 1258.74 1256.47 1.06 * Omics data 
mreB 11.83 12.25 12.24 12.42 1.03 * Omics data 
uxaC 12.84 13.26 11.88 14.83 1.03 * Omics data 
pflB 96.68 94.55 85.93 109.98 1.03 * 
Weak/no 
evidence 
ydcS 540.39 525.45 540.32 530.08 1.00 * 
Weak/no 
evidence 
cdd 80.91 80.86 85.70 74.89 0.99 * Omics data 
yeaH 35.97 40.87 36.26 38.97 0.98 *  
Weak/no 
evidence 
sdhB 147.39 130.73 142.81 122.92 0.95 *  Omics data 
wrbA 79.75 93.05 82.25 81.19 0.94 *  Omics data 
pdxB 40.75 37.59 38.65 34.27 0.93 * Omics data 
metC 15.45 15.12 14.37 14.15 0.92 *  
Weak/no 
evidence 
















proS 101.06 87.90 86.41 82.71 0.89  * Omics data 
glnS 108.10 80.69 75.56 90.69 0.88  * 
Weak/no 
evidence 
katE 151.39 176.62 131.69 139.92 0.82  * 
Weak/no 
evidence 
ompR 13.90 13.66 11.82 11.64 0.81  * 
Weak/no 
evidence 
guaA 13.51 13.26 12.07 10.65 0.81  * Omics data 
kdsA 172.96 148.19 129.01 130.16 0.8  * Omics data 
aroD 32.52 34.45 25.31 28.35 0.78  * Omics data 
yqjD 2745.61 2558.64 1388.67 2678.87 0.77  * Omics data 
pta 13.28 12.96 10.50 10.98 0.76   Omics data 
uxuB 41.52 37.47 31.77 29.17 0.75   Omics data 
purM 179.72 180.67 125.67 140.53 0.73   Omics data 
fhuA 11.82 11.07 9.51 8.89 0.73   
Weak/no 
evidence 
cspE 202.68 636.13 165.76 425.63 0.7  * 
Weak/no 
evidence 
iaaA 58.82 59.76 39.67 44.74 0.7   
Weak/no 
evidence 
glmS 14.18 13.00 10.38 10.21 0.69   Omics data 
mtlD 506.11 506.49 341.94 313.97 0.65   Omics data 
acs 2860.51 2987.32 1905.23 1823.10 0.64   
Weak/no 
evidence 
manX 24.66 28.91 15.67 18.32 0.59   
Weak/no 
evidence 
suhB 91.71 81.15 51.03 47.34 0.55   
Weak/no 
evidence 




The mRNA product of each gene that produced fluorescence is displayed here. 
The fluorescence values are from the biological replicates of samples with 
induced or uninduced CsrA. Fluorescence values are in arbitrary fluorescence 
units and are relative to each other. The repression ratio is the background 
fluorescence corrected average of the two fluorescence conditions. A * symbol 
indicates targets that had significant variation between replicates as compared to 
the repression ratio. The final column describes the evidence that was used to 
select the target for the assay.  
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Table 3.2: mRNA targets with no observable fluorescence 
Tested, not fluorescent 
adeP dacC frdA hdeB purl mlaA yadM yhcB 
adeQ dcrB frvB hflC rbbA nhaA yaji yhjG 
amyA ddlA fumA hipB rib nlpA ybiT yiaD 
arcA deaD gabD hlfC rpoE ntcA ybjP yihX 
argS dgcZ galM hyfR rpsR nuoC ycaK yiiS 
aroA dppA gatC isnH sapA nuoG ycdT yliE 
asd fbp ghrA ldcC slp oppA ydcJ yliF 
cbpA feoB glgB ldtA sucB pntA ydgA yqjE 
clpS fepA glnH lon tamA potD yeaG yqjG 
cyoA fes gmk lrhA tgt pqqL yeaY ytfQ 
cyoB flhC gpt maeA thiM ptsP yebF   
cysI flhD hcaT mdtA topA purE yfhM   
cysP fliY hdeA mdtE tyrR purK yhbO   
 
The maximum observable repression by CsrA was dependent upon the rate of cell 
division. Since GFP is such a stable molecule, the only way that GFP concentration is 
reduced is by cell division splitting the available pool of GFP by half for each division. 
For this reason, the maximum observed repression rate was 2
-n
, with n being the number 
of cell divisions that took place. In this system, cell division was previously characterized 
as having roughly a doubling rate of 30 minutes without CsrA induction and between 30 
and 60 minutes with CsrA induced (93). This allows for 3-6 cell divisions to occur within 
the 3 hours between CsrA induction and the fluorescence measurement (Section 3.4.2). 
This means that the maximum observable repression ratio was between 8 and 64. It 
should be noted that the doubling rate observed was highly variable between targets. 
Given this interpretation of repression, we observed that many mRNAs displayed nearly 
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total repression of translation, suggesting that CsrA is directly responsible for inhibiting 
the target.  
Interestingly, not all targets that appeared to be inhibited by CsrA displayed total 
inhibition by CsrA; lower levels of repression were also observed. There are three 
possible scenarios to explain partial inhibition by CsrA: 1) indirect effects from CsrA 
expression are responsible for the observed inhibition, 2) CsrA interaction does not 
completely inhibit the target but instead creates a structural change in the transcript that 
alters translation rate, or 3) CsrA binding to the target mRNA is weak and incomplete, 
allowing there to be a mixture of bound and unbound transcript in the cell. The design of 
this assay was meant to mitigate the first scenario. The plasmid based system removes 
transcription from its natural regulation, but other post-transcriptional control 
mechanisms could be still effect the expression of the target. For example, CsrA controls 
expression of Hfq (36); any mRNAs that depend on Hfq would be indirectly affected by 
CsrA. The second scenario is likely true for some targets, but verification of this 
mechanism would require more characterization of the mRNA target.  The third scenario 
is perhaps the most interesting possibility, as it has implications for the mechanism of 
CsrA based regulation. It is well documented that CsrA does not have equal affinity 
towards all mRNA targets, so the situation caused by weak CsrA affinity has to be true. 
This raises the question as to how much CsrA can be tuned naturally to affect different 
mRNAs at different cellular conditions.  Differential affinities could create tunable 
mRNA activity. This mechanism for a global regulator is definitely a unique possibility 
that requires further exploration.  
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In addition to inhibition, several evaluated mRNAs also display the potential for 
activation by CsrA. As can be seen in Table 3.1, many genes display repression ratios 
significantly less than 1.0 (indicating that CsrA induction increased the observed 
fluorescence). While many of these targets were predicted to be activated by CsrA in our 
previously mentioned omics data, it is not possible to verify that these genes are truly 
activated by CsrA and not the result of indirect changes caused by CsrA. As mentioned 
previously, CsrA induction had the potential to alter the rate of cell division in some 
targets. If the cell division rate decreased while the translation rate of the gene remained 
constant, then the overall fluorescence observed would increase. In order to verify the 
relationship of CsrA and the mRNA target, there needs to be careful monitoring of cell 
division to ensure that the growth rate was not a major contributing factor to the increase 
in fluorescence intensity. 
An important point to consider when evaluating the relationship between CsrA 
expression and fluorescence activity is that this test does not prove that CsrA is directly 
interacting with the mRNA. Although it is very likely that the most repressed targets are 
directly interacting with CsrA, it is possible that the observed repression could be the 
result of other unexpected indirect interactions. Due to the lingering concern that indirect 
actions are responsible for the observed behavior, it is necessary to prove that CsrA is 
directly interacting with the target mRNA. The remainder of this chapter presents our 
attempts to detect the direct interaction of CsrA with the target mRNA using 
modifications to the TriFC method presented in Chapter 2.  
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3.2.4 Modification of TriFC conditions to detect mRNA-CsrA interactions 
In the TriFC method presented in Chapter 2, we developed a method that was 
capable of detecting the interaction of CsrA with the sRNA, CsrB, using molecular 
fusions to direct fluorescence complementation. In order to modify this system to be a 
diagnostic tool for mRNA-CsrA interactions, the RNA portion of the system had to be 
changed to produce the mRNA of the targeted genes.  
The alteration of the RNA fusion for mRNA sequences has two major concerns: 
1) the distance between a potential CsrA binding site and the MS2-binding site has to be 
close enough to promote refolding of the YFP fragments and 2) the mRNA has to be 
stable and properly folded to allow CsrA binding. These two concerns were less of an 
issue in the original system with CsrB because of the way CsrB binds CsrA. With regards 
to the first concern, CsrB has multiple sites that bind to CsrA, so the MS2-binding site is 
guaranteed to be near a CsrA binding site. Since the length of some mRNAs can be 
thousands of nucleotides, the location of the MS2BD needs to be considered carefully. 
The only location to attach the MS2-binding site is at the 5’ UTR of the targeted mRNA. 
This is the most logical place, since CsrA binds in or near to the 5’UTR of regulated 
mRNAs.  
The position of the MS2-binding site raises the concern that the transcriptional 
instability present in the MS2-binding region (section 2.2.4) would prevent production of 
the full transcript or create secondary structure unusual to the gene in question.  To show 
that the targeted mRNA is being produced, the mRNA sequence of interest was designed 
to create a translation fusion with a red fluorescent protein (mStrawberry).  The presence 
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of the fluorescent protein would indicate that the mRNA fusion was present and that it 
was capable of attracting a ribosome regardless of any potential structural changes to the 
mRNA. This is important to the stability of the mRNA, as translation is known to 
stabilize mRNA transcripts (94). The modifications to TriFC system and the plasmids 




Figure 3.2: Modifications to CsrA TriFC for mRNA target identification 
A) Schematic of CsrA TriFC – The two protein components used to create a 
fluorescent interaction are unmodified from the system discussed in Chapter 
2. The RNA fusion is modified to create the MS2 binding domain at the 5’ 
end of the mRNA target of interest. The mRNA produced a translational 
fusion with mStrawberry to produce a signal indicating the presence of the 
mRNA transcript. 
B) The two plasmid system to produce the components of the TriFC system. 
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As a result, of the modifications to the TriFC system presented in Figure 3.2, cells 
produce two fluorescence signals, red and yellow. The yellow fluorescence is an 
indication of fluorescence complementation and is controlled by the interaction of CsrA 
and the mRNA target. The red fluorescence is the result of translation from the mRNA 
target.   
3.2.5 TriFC provides affirmation of CsrA-mRNA interactions from translational 
assay 
70 mRNA targets were selected to be tested by TriFC. Of these targets, 31 targets 
displayed increased yellow fluorescence over a negative control, indicating an 
mRNA-CsrA interaction. The negative control was the fecA mRNA which was shown not 
to be regulated by CsrA in 5’UTR assay (see Methods 3.4.6). Table 3.3 presents all of the 
mRNAs tested, the fluorescence emission corrected for cell concentration, the standard 
deviation, and the p-value (in relation to the negative control). Additionally, Table 3.3 
includes an assessment of the data, indicating mRNAs that are likely directly interacting 
with CsrA. Any targets that displayed a higher average fluorescence than the negative 
control and also passed a Student’s t-test with a value of p<0.1 were labelled as targets 
identified by TriFC. We used a slightly higher p-value because the fluorescence from 
TriFC had significant variation between replicates for some samples. If the fluorescence 
was significantly lower than the control, these targets were declared as having “No 
enhancement of TriFC.” Targets that had failed the t-test were labelled as “evidence 
inconclusive.”  
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It is interesting to note that many targets displayed fluorescence that was 
significantly lower than the fluorescence observed in the negative control. An explanation 
for this phenomenon is that CsrA may be attracted to the target, but CsrA binding is in a 
position that sterically hinders YFP complementation. Additionally, for some mRNA 
targets with highly active red fluorescence production, it is possible the mStrawberry 
could interfere with the observed yellow fluorescence by absorbing the emission spectra 
of YFP. In either case, it is important to understand that TriFC is only a positive test for 
CsrA binding to a target mRNA and that that a negative result does not indicate that CsrA 
is not interacting with a target. To illustrate this point, five mRNAs were tested that that 
had documented interactions with CsrA. These mRNAs were glgC, pgaA, hfq, cstA, and 
nhaR. While glgC, nhaR, and pgaA all displayed enhanced fluorescence, cstA and hfq 
failed to show enhanced fluorescence. 
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Table 3.3: Summary of TriFC expression for selected mRNA targets   
 
mRNA EM530/OD900 stdev p-value Outcome 
fecA (*) 282 17 0.5 negative control 
ahr 172 12 0.007 
no enhancement of 
TriFC 
acnA 491 145 0.072 Target 
aidB 352 28 0.02 Target 
amyA 349 31 0.027 Target 
aroD 225 5 0.04 
no enhancement of 
TriFC 
bfr  164 34 0.008 
no enhancement of 
TriFC 
carB 126 22 0 
no enhancement of 
TriFC 
cdd 592 95 0.013 Target 
clpB 1022 283 0.022 Target 
csiD 235 37 0.087 
no enhancement of 
TriFC 
cstA 284 9 0.452 evidence inconclusive 
cysK 157 10 0 
no enhancement of 
TriFC 
dps  1626 57 0 Target 
dsrB 155 16 0 
no enhancement of 
TriFC 
elaB 195 22 0.003 
no enhancement of 
TriFC 
entF 387 218 0.245 evidence inconclusive 
evgA 1011 219 0.014 Target 
fbp   465 98 0.035 Target 
fdoH 503 78 0.018 Target 
fepA 255 61 0.293 
no enhancement of 
TriFC 
frdB 335 201 0.334 evidence inconclusive 
gadA 229 53 0.112 
no enhancement of 
TriFC 
gadB 1033 314 0.027 Target 
gadC 597 119 0.021 Target 
glcB 169 32 0.006 
no enhancement of 
TriFC 
glgC 381 13 0.009 Target 
glsA 881 112 0.005 Target 
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Table 3.3 (continued) 
mRNA EM530/OD900 stdev p-value Outcome 
groL 390 119 0.127 evidence inconclusive 
gstA 964 419 0.053 Target 
guaA 131 21 0 
no enhancement of 
TriFC 
hemX 199 6 0.059 
no enhancement of 
TriFC 
hflK 226 39 6 
no enhancement of 
TriFC 
hfq  137 26 0.001 
no enhancement of 
TriFC 
kdsA 427 136 0.242 evidence inconclusive 
ldtA 629 3 0 Target 
lsrF 186 2 0.016 
no enhancement of 
TriFC 
ltaE 122 8 0 
no enhancement of 
TriFC 
moaB 278 82 0.472 
no enhancement of 
TriFC 
nhaR 548 36 0 Target 
nuoC 276 66 0.451 
no enhancement of 
TriFC 
nuoG 173 22 0.001 
no enhancement of 
TriFC 
ompC 175 8 0.01 
no enhancement of 
TriFC 
osmE 267 100 0.412 
no enhancement of 
TriFC 
patA 488 8 0 Target 
pck  216 78 0.141 
no enhancement of 
TriFC 
pgaA 703 271 0.057 Target 
pgm  332 28 0.034 Target 
phoU 160 7 0.008 
no enhancement of 
TriFC 
proP 858 393 0.063 Target 
purM 274 114 0.461 
no enhancement of 
TriFC 
rib 340 17 0.03 Target 
rpoS 453 59 0.014 Target 
sdhA 494 9 0 Target 
sucC 330 13 0.047 Target 
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Table 3.3 (continued) 
mRNA EM530/OD900 stdev p-value Outcome 
tauD 176 22 0.002 
no enhancement of 
TriFC 
thiG 523 48 0.004 Target 
uspG 485 146 0.067 Target 
uxaC 241 84 0.25 
no enhancement of 
TriFC 
ybaL 336 34 0.045 Target 
ybeL 145 22 0.002 
no enhancement of 
TriFC 
ybiT 344 39 0.046 Target 
ydhQ 288 63 0.442 evidence inconclusive 
ydjA 245 51 0.167 
no enhancement of 
TriFC 
yebE 620 62 0.004 Target 
yecC 518 14 0 Target 
yhjI 172 29 0.005 
no enhancement of 
TriFC 
yhjG 659 13 0 Target 
yiiS 226 23 0.016 
no enhancement of 
TriFC 
yibD 514 68 0.011 Target 
yqjE 302 5 0.172 evidence inconclusive 
ytfQ 206 42 0.038 
no enhancement of 
TriFC 
 
mRNA targets were evaluated with TriFC by measuring the fluorescence 
emission at a wavelength of 530 nm (EM530). This value was normalized by the 
optical density at 900 nm (OD900) and an average value was taken for three 
measurements (see Methods 3.4.5). Values of fluorescence were compared to the 
fecA control (marked with a *). mRNAs that had statistically higher fluorescence 
(p-value) were labelled with an outcome of “target.” mRNAs that failed the 
significance test were labelled as “evidence inconclusive.” mRNAs that didn’t 
appear to have enhanced fluorescence were labelled “no enhancement of TriFC.”  
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3.2.6 Comparison of 5’UTR data TriFC complements translational assay data  
 In this assay, 32 targets were identified as having elevated TriFC readings as 
compared to a control. These targets are compared to the repression ratio from the 
translation assay presented in Table 3.1. The summary of this comparison appears in 
Table 3.5. While 8 targets are waiting for the data from the 5’UTR-translation assay 
(marked as “-”), only 2 genes did not display sensitivity to CsrA induction, cdd and yjbD 
(marked with a “*”). This means that the TriFC assay and the 5’UTR translational assay 
provide direct experimental evidence that CsrA directly binds to and regulates these 19 
mRNA targets. This number excludes glgC, pgaA, and nhaR, which have been previously 
characterized as CsrA binding transcripts. While many of these targets have been 
suggested as CsrA targets based on previously published omics studies (21, 41), this 
work represents direct experimental evidence of CsrA both interacting with and having a 
regulatory effect on these targets.      
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Table 3.4: Comparison of TriFC targets and observed ratio change in fluorescence 
activity  
mRNA TriFC result Repression ratio 
cdd target 0.99 
yjbD target 1.09 
yecC target 1.53 
yebE target 1.79 
sucC target 1.81 
fdoH target 2.45 
ybaL target 2.51 
nhaR target 2.87 
sdhA target 3.11 
evgA target 3.22 
dps target 3.53 
proP target 3.54 
gadB target 3.55 
pgm target 3.70 
rpoS target 3.83 
clpB target 3.91 
pgaA target 4.15 
gstA target 5.73 
acnA target 7.91 
uspG target 9.13 
thiG target 11.07 
aidB target 16.93 
glsA target 19.01 
glgC target 44.94 
amyA target - 
fbp target - 
gadC target - 
ldtA target - 
patA target - 
rib target - 
ybiT target - 
yhjG target - 
 
This table displays the repression ration from Table 3.1 for the mRNAs that were 




 The work represents one of the most extensive characterizations of CsrA 
regulation with over 241 mRNAs evaluated for translational regulation by CsrA. Of these 
241 targets, 94 targets displayed statistically significant changes in translation in 
relationship to CsrA. The modification to the TriFC tool developed in Chapter 2 created 
an in vivo system for the identification of mRNAs that interact with CsrA that provided 
evidence of 32 targets interacting with CsrA. With these two assays, a total of 19 
previously unrecognized mRNAs were identified as CsrA targets. 
 Examination of the targets identified with these two assays has significant impact 
to the understanding of CsrA regulation. The implication that CsrA regulates uspG (the 
protein is a substrate of GroEL) and clpB (a protein folding chaperon) ties CsrA into the 
heat stress response. The regulation of aidB and dps shows that CsrA plays a role in 
responding to and preventing damage to DNA. The regulation of evgA (a transcriptional 
regulator of acid response genes) ties CsrA into regulation of acid stress response, which 
explains previous findings that CsrA had a relationship to the acid response in H. pylori 
(95). The regulation sdhA and sucC (genes that produce succinate) show how CsrA is 
involved in the citric acid cycle and even suggests that modifications to the Csr system 
could be a productive strategy to improve the fermentation of succinate (96).  
Most notably, the sigma factor rpoS appears to be inhibited by CsrA. As a sigma 
factor, RpoS is responsible for transcriptional control of numerous genes with specific 
control over stress response genes and stationary phase genes. As these two functions are 
responsible for major cellular changes, the finding that CsrA controls RpoS concentration 
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provides an explanation as to how CsrA can be involved with so many genes. 
Additionally, it is known that RpoS is partially responsible for transcription of csrA (97), 
the implication that CsrA inhibits its activators suggests that the cell can carefully titrate 
CsrA expression to meet certain conditions.  
While the total number of targets verified by TriFC is much smaller than we had 
hoped, it is important to clarify that the TriFC test only provides affirmation of targets 
interacting with CsrA. Since the test is expected to fail to identify targets due to steric 
factors associated with the position of CsrA binding, a negative result for TriFC binding 
does not indicate that there is no interaction between CsrA and the target. Given that the 
94 targets that responded to CsrA expression display a wide range of relationships to 
CsrA activity, including what can be interpreted as total inhibition of translation, it is 
likely that many of these genes are actually regulated by CsrA. Furthermore, the number 
of targets analyzed in this translational assay represents the largest biophysical-
mechanistic characterization of the Csr system. In the following chapter, we present a 
model that interprets the findings of this mechanistic characterization of CsrA and has 
implications for CsrA function.   
3.4 METHODS 
3.4.1 Plasmid creation for translational Assay 
The translation assay presented here is a modified system of translation assay 
presented in previously published work (93). Selected target sequences were created by 
genomic PCR amplification off of MG1655 E. coli or produced through Genscript DNA 
synthesis services. Selected targets were inserted into plasmid pHL1756 between the SalI 
 75 
and SphI cut sites to create the test plasmid. Two methods were used to create the 
pHL1756 variants, either standard restriction site cloning or Gibson assembly. The 
plasmids, pHL1756 and pHL600, and the strain HL4142 are all available through 
Addgene ® services. A complete list of primers used to amplify genomic DNA is found 
in Appendix Table A.2. 
3.4.2 Growth conditions and fluorescence measurement for translational assay 
To perform the experiment, cells from the strain HL4142 were transformed with 
the plasmid pHL600 followed by a second transformation of the gene specific variant of 
pHL1756 (both using a CaCl2 chemical transformation technique). Colonies of cells 
containing both plasmids were grown overnight to be used to inoculate two separate 
250mL flasks containing 10 mL of fresh LB media. Overnight culture was added to the 
fresh media at a ratio of 1:50. These cells were grown at 37°C with agitation to an 
approximate OD600 of 0.3, which typically took between 2-3 hours. At this time, one of 
the two inoculated flasks was induced to express CsrA by adding IPTG to a final 
concentration of 0.1 mM. This set up compares the conditions of CsrA induced and 
uninduced. Each mRNA target was tested with biological duplicates.  
Fluorescence was measured 3 hours after inducing CsrA by flow cytometry on a 
FACSCalibur flow cytometer (BD Biosciences). This amount of time was chosen in 
order to balance the need to limit the accumulative effects of indirect regulation caused 
by CsrA induction with the need to allow enough cell divisions to dilute GFP 
concentrations (GFP is very stable). The fluorescence ratio has been corrected for the 
background fluorescence by subtracting 3 fluorescence units from the average value. The 
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background fluorescence is an approximated value because there was considerable 
variation around this value between day to day measurements. The lowest fluorescence 
value observed varied between 3 and 8 units (the lowest reading was actually 2.5 for 
some inactive targets). The distinction between 3 and 8 units could produce significant 
changes in the observed ratio of repression for targets with weaker fluorescence. 
However, the uncertainty around the background fluorescence only affects a small 
portion of targets. 
3.4.3 Identification of targets effected by CsrA induction 
The ratio of the mean fluorescence of the population expressing CsrA relative to 
cells not expressing CsrA was calculated to determine if CsrA expression altered 
translational activity of the mRNA. Constructs were tested in biological duplicate to 
verify that the observed trends were reproducible and statistically significant. If the 
Student’s t-test comparing an mRNA’s fluorescence with CsrA induced and non-induced 
produced a p-value less than 0.1, that target was labelled as affected by CsrA. Targets 
that failed the t-test were marked by the * symbol in Table 3.1. 
3.4.4 Construction of TriFC plasmids 
The TriFC plasmids used in the system were derived from the plasmids used in 
our previously published work with CsrA-CsrB TriFC (98). The MS2-CYFP expressing 
construct is unmodified from the original plasmid presented in Chapter 2. The test 
plasmid pCsrA-NYFP+MS2bd-5’UTRCDS-mstrawberry was constructed from that 
study’s plasmid pCsrA-NYFP+2MS2bd (presented as a control in Chapter 2). This 
plasmid was modified by the insertion of the sequence speI-RBS-sphI-mstrawberry-aatII 
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purchased from Genscript (Appendix A.3). The sequence was inserted into the plasmid 
between the SpeI and AatII cut sites following the 2MS2bd sequence. This sequence 
introduced a ribosome binding site and a start codon that would produce mStrawberry. 
Additionally, a SphI cut site was created preceding the mStrawberry sequence so a 100 
nucleotide length of coding sequence inserted at the SphI site would be in frame with the 
sequence of mStrawberry. 
The mRNA sequences of selected genes tested via TriFC were identical to the 
sequence tested in the translation assay. Sequences were created by through Genscript ® 
or from a genomic PCR. All sequences were inserted into the plasmid pCsrA-
NYFP+MS2bd-5’UTRCDS-mstrawberry at the restriction sites of SpeI and SphI.  All 
sequences were verified by the ICMB Core Facility sequencing facility available at the 
University of Texas at Austin. For a complete list of targets tested with the sequence 
used, please see Appendix A.1. 
3.4.5 Test conditions for TriFC 
The TriFC plasmids and the MS2-CYFP containing plasmid were transformed 
into a strain with no native expression of CsrB, ΔcsrB trMG1655 (courtesy of Tony 
Romeo (25)). The strain was chosen to prevent CsrB from interfering with the TriFC 
interaction. This is identical to the strain used in Chapter 2. 
To create the two plasmid system needed for TriFC the strain ΔcsrB trMG1655 is 
transformed with two sequential transformations. The plasmid pMS2-CYFP is 
transformed into the strain first using CaCl2 chemical transformation methods. Cells 
containing pMS2-CYFP are made competent and transformed with the TriFC plasmid 
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(also using CaCl2 chemical competent transformation). The transformed cells are grown 
on plates carrying the appropriate antibiotic conditions (carbenicillin and kanamycin).  
For each mRNA sequence tested, three colonies were picked and inoculated into 
5mL of LB in the presence of carbenicillin and kanamycin at concentrations of 100 
µg/mL and 50 µg/mL, respectively. The cells were grown for 18 hours after inoculation. 
It was not necessary to induce the expression of the TriFC constructs because the ΔcsrB 
strain constitutively expressed the constructs (discussed in Chapter 2). At this point, the 
cells are harvested and measured for fluorescence. 
The cells are harvested by pelleting 1 mL of saturated liquid culture in 1.5 mL 
conical centrifuge tube. The LB supernatant is decanted and the cells are re-suspended 
with 1 mL of phosphate buffered saline solution (PBS) and pelleted a second time 
followed by removal of the PBS supernatant. The cells are re-suspended again in 1 mL of 
PBS.  Fluorescence is measured by plate reader using the Cytation3 Imaging Reader. 300 
µL of the washed cell culture is loaded into a 96 well plate that is black with clear bottom 
(Corning Costar Assay Plate). Fluorescence is excited with a 470 nm laser wavelength, 
and the fluorescence emission is measured at 530 nm using spectral scanning. This 
measurement is normalized by reading the optical density at 900 nm (OD900). The 
wavelength of 900 nm was chosen to avoid potential interference by the mStrawberry 
protein that could occur with a traditional 600 nm optical density reading. The 
fluorescence was reported as fluorescence units per OD900 units, with OD900 being 
corrected using a PBS blank. 
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3.4.6 Establishing a fluorescent control for system 
To establish a fluorescence control, mRNA targets were chosen from the currently 
unpublished omics data referenced in “Target selection” that displayed little relationship 
to CsrA. These mRNAs were tested in the 5’UTR translation assay to assess their 
sensitivity to CsrA, and it was determined that the gene fecA was not sensitive to CsrA. 
Since it was expected that fecA would not interact with CsrA, the fluorescence from fecA 
TriFC should represent the background recombination of YFP. To compare different 
targets to fecA, the fluorescence emission spectra of several mRNA targets were 
measured as described in the Section 3.4.5 of the methods. The spectral intensity of select 




Figure 3.3: Spectral fluorescence emission of selected targets in the TriFC system 
The curves are of the fluorescence intensity measured at specific 
wavelengths for different genes being tested in the TriFC system. The two 
peaks in the spectra relate to the two fluorescent proteins present in the 
system, with the peak at 530 nm coming from refolded YFP fragments and 















































In Figure 3.3, the two fluorescence proteins are clearly visible by the presence of 
an emission peak at 530 nm, corresponding to recombined YFP, and at 600 nm, 
corresponding to mStrawberry. The targets aroD, acnA, glgC and hfq display 
significantly higher fluorescence at 530 nm than the targets fecA, sucC, cysK, and an 
artificial RBS control (mentioned in 3.4.4). The interpretation of this result is that these 
targets are enhancing yellow fluorescence as a result of CsrA-target interactions. It 
should be noted that hfq and glgC are documented targets of CsrA, which reinforces the 
interpretation that CsrA is directing fluorescence complementation. Additionally, it can 
be seen that the intensity of the fluorescence from mStrawberry varies with respect to the 
targets being tested. The mStrawberry fluorescence is dependent upon the translational 
activity of the target gene, which could be affected by CsrA regulation. However, there 
appears to be no correlation between yellow fluorescence and red fluorescence, 
suggesting that the TriFC measurement is independent of red fluorescence. 
To establish the statistical significance of the fluorescence measurements taken, 
all targets were tested in biological triplicates. Using the fecA target as a control, the 
Student’s t-test was performed for all targets with an average yellow fluorescence value 
greater than that of fecA. For the purposes of identifying targets that show enhanced 
TriFC, a p value of 0.1 was used as a cut off. The emission summary of the targets 
displayed in Figure 3.3 appears in Table 3.4. 
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Table 3.5: Summary of fluorescence emission from triplicates of targets presented in 
Figure 3.3 
 
As can be seen in the comparison shown in Table 3.5, the targets aroD, acnA, and 
glgC have a significantly larger amount of yellow fluorescence as compared to the fecA 
control. The other replicates of the known CsrA target hfq were not as fluorescent as the 
replicate depicted in Figure 3.3. This means that the target hfq can not be declared a 
target using TriFC data because it fails to past the Student’s t-test for significance. 
Expanded testing of sucC suggested that fluorescence presented in Figure 3.3 is indeed an 
outlier and that sucC is probably a target (presented in Results 3.2.4).  The issue with hfq 
and sucC is representative of the TriFC system. Some mRNAs will display a wide range 
of fluorescence capabilities between biological replicates, making it difficult to determine 
if the gene is interacting with CsrA by standard statistical methods. It is likely that 
mRNAs that display enhanced yellow fluorescence inconsistently are likely CsrA targets 



























aroD 653 52 0.002 610 32 
cysK 309 12   556 26 
acnA 722 214 0.072 792 233 
sucC 401 203   521 101 
hfq 405 317   1190 761 
glgC 682 106 0.01 300 49 
rbs 235 10   1893 87 
fecA 415 45   529 39 
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For the purposes of comparing measurements taken on different days, all 








As computational methods advance in sophistication and efficiency, researchers 
turn to in silico methods to create models capable of informing and predicting biological 
behavior. For regulatory RNAs, most modelling efforts are focused on sRNA-mRNA 
interactions and have largely ignored other regulatory RNAs. These sRNA-mRNA 
models benefit from the understanding of base-pair interactions and focus largely on the 
prediction of mRNA targets (67, 99-101).  These models make no effort to predict the 
extent of the regulatory interaction, but they are valuable for directing more in depth 
characterizations of sRNA-target interactions. Currently, few models exist for other 
regulatory RNA interactions due to the lack of a mechanistic understanding of the 
specific interactions. 
Compared to the well understood base-pair interactions of sRNA-mRNA 
regulation, there are no generalizable strategies for the modelling of RNA-protein 
interactions. Each RNA-protein interaction must be characterized individually to develop 
the knowledge to predict the system’s behavior. Characterizations of RNA-protein 
interactions utilize the techniques of SELEX (54), SEQRS (102), and CLIP (51) to 
identify the protein’s RNA recognition motif. However, these methods have been 
criticized as being biased towards identifying the highest affinity targets and potentially 
missing biologically relevant lower affinity targets (52). The quality of the interaction 
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motif characterization is of great importance because the motif can be used for target 
predictions similar to methods using sRNA motifs to predict mRNA targets.  
With regard to the protein CsrA, SELEX and CLIP experiments have verified that 
CsrA recognizes GGA motifs, AAGGA specifically, with high affinity (29, 41) .  The 
GGA motif has been used to make simplistic predictions of CsrA’s mRNA targets that 
are based on either the presence of the GGA motif near the RBS or the prevalence of the 
motif in the transcript (21, 46). In the former case, hundreds of mRNA targets are 
predicted to interact with CsrA, which is likely too broad of a prediction. Conversely, the 
method that identifies targets based on the prevalence of the motif is likely too selective, 
identifying only a specific set of targets. Furthermore, these predictions formulated from 
sequence similarities to the recognition motif are solely qualitative and lack quantitative 
information that could explain CsrA behavior on these mRNAs.  
In this work, we developed a biophysical model that predicts CsrA binding 
interactions and provides an assessment of the affinity of the interaction. The predictions 
of this model are interpreted through a published biophysical interpretation of translation 
initiation (the RBS Calculator) (103) in order to predict the regulatory significance of the 
CsrA-RNA interaction. This model’s predictions are validated with experimental 
evidence of regulation based on the translational assay presented in Chapter 3. 
Furthermore, the quantitative nature of the model was investigated with experiments that 
demonstrate in vivo titration of specific mRNA transcripts. The combination of the 
binding site prediction and the effect it plays on translation presents a novel model to 
predict an mRNA interaction’s potential with CsrA. Beyond target predictions, this 
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model provides a qualitative prediction of the affinity of mRNA-CsrA interactions that 
creates a rational basis to explain how CsrA fine-tunes expression of multiple targets.  
4.2 RESULTS 
4.2.1 CsrA binding model 
The free energy model presented in this chapter was created from the first 
principles describing CsrA-RNA interactions and predicts the affinity of CsrA with any 
given sequence of RNA. This model makes four basic calculations to predict the most 
likely site for CsrA to bind to and predicts how binding at this site affects translation 
initiation (Figure 4.1). These steps ultimately determine: 1) all the minimum free energy 
structures for the RNA bound to CsrA and 2) the translation initiation rates of each of 
these structures. In this model, the RNA sequence analyzed is the 5’UTR and the first 
100 nucleotides of the coding sequence of an mRNA. For comparison purposes, the 




Figure 4.1: Calculations to determine CsrA affinity and effect on translation 
These four panels represent the four steps that the model uses to predict the 
position, affinity, and regulatory effect that CsrA will have on an mRNA 
sequence.  
Step 1 – The model scans the sequence for 5 nucleotide fragments that have a 
similarity to the AAGGA motif and assigns an initial free energy score according 
to the position weight matrix. 
Step 2 – The model calculates the free energies of all pairs of sites identified in 
Step 1. An additional free energy term is added based on the distance between the 
sites. 
Step 3 – The model calculates the minimum free energy of the RNA structure that 
will permit CsrA to bind the sites identified in Step 2. 
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Step 4 – The model uses the predicted RNA structure of the transcript bound by 
CsrA and free of CsrA to modify the RBS Calculator to predict the overall effect 
that CsrA binding has on translation.  
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 The first step of the model is to determine primary CsrA binding sites. In bacteria, 
CsrA binding sites have been characterized as containing an ANGGA motif (29, 31, 32). 
Specifically, SELEX experiments defined the motif for E. coli CsrA as AAGGA and 
identified the changes in Kd that occurred when each nucleotide in the AAGGA motif is 
mutated. (29). From this experiment, a position weight matrix (PWM) was made to 
describe the ΔG associated with each nucleotide in the motif (Table 4.1). 
Table 4.1: Position weight matrix of CsrA binding site 
A U G C 
-2.63 0 0 0 
-2.20 0 0 0 
0 0 -3.14 0 
0 0 -3.14 0 
-1.65 0 0 0 
Each nucleotide in a sequence that matches the sequence AAGGA is assigned an 
individual free energy contribution according to its position in the motif. 
 
This PWM creates estimations for CsrA affinity (ΔGprotein_binding) for every set of 5 
nucleotides in a sequence. This method of identifying CsrA binding sites also broadens 
the search beyond the traditional standard of requiring a GGA sequence within the motif 
(21, 45). It is important to note that the experiment defining the PWM only performed 
one mutation of the AAGGA motif, so it is only possible to calculate the free energy 
contributions of AAGGA and no other nucleotides that may be able to contribute. In 
addition, other efforts using molecular modelling to determine the energetic contributions 
of individual nucleotides have determined slightly different energetic values (31).  
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 Using the PWM, the full sequence of a given UTR was scanned for five 
nucleotide sequences with ΔGprotein_binding less than 0, and all sites that met this criterion 
were identified and sorted by lowest to highest ΔGprotein_binding (Figure 4.1-1).  
Since CsrA is known to bind multiple sites on a transcript (19, 37), the model for 
likely CsrA binding sites was extended to include free energy estimations for CsrA 
binding two sites simultaneously. The minimum free energy of all unique pairs of single 
CsrA sites was calculated as the sum of their individual ΔG’s of CsrA binding (Figure 
4.1-2).  
   ΔGpair_sites = ΔGprotein_binding_1 + ΔGprotein_binding_2 
In addition to the consideration that CsrA can potentially bind to two RNA sites, 
previous research observed that pairs of sites often bind to the same CsrA when the 
distance between the sites is between 10 and 50 nucleotides (32). This observation 
suggests that RNA sites bind to CsrA cooperatively. To account for this cooperativity, the 
term ΔGdimerization was added to the model to provide an additional ΔG bonus for CsrA 
binding sites between 10-50 nucleotides apart. The ΔGdimerization is calculated with the 
following equation:  
ΔGdimerization = 0.001d
2
 + 0.05d – 5.0 
where d is the number of nucleotides between the two predicted sites 
when d ≤ 11, Steric penalty of ΔG = 20 
Representing dimerization in this way provides a diminishing dimerization bonus for 
sites as they become more separated (with no bonus given after 50 nucleotides).  
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The model calculates the minimum free energy of a possible CsrA interaction as 
sum of the single CsrA binding sites identified by the PWM and the dimerization term. 
The free energy of CsrA binding to a pair of sites is depicted below: 
ΔGpair_sites = ΔGprotein_binding_1 + ΔGprotein_binding_2 + ΔGdimerization 
The presented model for CsrA binding makes two major assumptions for how 
CsrA interacts with RNA. The first assumption is that CsrA binds to two sites and each 
site has an accumulative effect, and the second assumption is that the distance between 
these sites can positively influence the affinity of the interaction. As part of the 
evaluation of this model, we decided to evaluate the assumptions to determine if they 
were meaningful to the physical interaction. This was accomplished by altering the free 
energy model to neglect the contributions of either the dimerization term or the second 
site. Effectively, this created three different models that predicted different CsrA binding 
sites. The first model assumes that CsrA only binds to one site on the mRNA and 
recognition depends exclusively on the PWM (Single site model). The second model 
allows CsrA to bind to two sites, but CsrA receives no bonus from the relative position of 
the two sites (Two site model). Finally, the third model is the previously described model 
(Dimer model). These three models created different ΔG predictions for predicted sites 
which changed the prediction of the most likely binding site.  These three models are 
evaluated in the following section (Section 4.2.2).  
Once all possible combinations of CsrA binding sites had been determined using 
the three different model assumptions, a minimum free energy structure was calculated 
for all CsrA binding sites predicted using ViennaRNA (104, 105) (Figure 4.1-3). The 
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structure of CsrA bound mRNA was defined as the most stable RNA structure that leaves 
the predicted binding sites free of secondary structure. The structure of the 5’ UTR 
unbound by CsrA was calculated and used to predict the energy change that results from 
the change in RNA structure caused by CsrA binding. The energy change of the RNA 
structure bound to CsrA is presented below: 
ΔΔGmRNA = ΔGbound_structure – ΔGunbound. 
This energy change based on the RNA structure was the final term used to 
calculate the overall ΔG of CsrA binding. Depending on the model assumptions being 
used, the free energy predictions for CsrA binding sites were based on the similarity of a 
site (or sites) to the PWM, the distance between that site and a second site, and the 
structural change that occurs to allow CsrA to bind at those positions. The most likely 
predicted structure (lowest free energy) was input into the RBS Calculator (106) to 
determine the translation initiation rate of CsrA bound mRNA (Figure 4.1-4). 
 For unbound mRNA transcripts, the RBS Calculator predicted a ΔGtotal of 
translation initiation using the following equation:  
 ΔGtotal = (ΔGmRNA:rRNA + ΔGstart + ΔGspacing  - ΔGstandby) - 
 ΔGmRNA_structure 
Where ΔGmRNA:rRNA, ΔGstart, ΔGspacing , and ΔGstandby, are ΔG terms that described 
mRNA binding to the ribosome, and the term ΔGmRNA_structure is the energy required to 
alter the RNA structure to allow ribosome binding (106). The RBS Calculator calculated 
the translation initiation rate (TIR) using a partition function relating ΔGtotal to TIR: 
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    TIR = e
-(βΔGtotal)
  
Where the Boltzmann constant, β, was previous determined to be 0.45 ± 0.05 
mol/kcal in previous studies (106, 107).  
The structural consideration for CsrA binding was introduced into the equation 
through modification to the ΔGmRNA_structure term to create the new term ΔGbound_structure. 
This term accounts for the energy change required to alter the structure of the RNA 
bound by CsrA to allow ribosome binding and is relative to the original ΔGmRNA_structure. 
Functionally, the modification fits into the ΔGtotal as follows: 
  ΔGtotal = (ΔGmRNA:rRNA + ΔGstart + ΔGspacing  - ΔGstandby) – ΔGbound_structure
 Since the ΔGbound_structure is relative to the ΔGmRNA_structure term, it can be positive, 
negative, or neutral with regards to the ribosome binding. If CsrA binding to a transcript 
causes the RNA to adopt a structure that blocks the ribosome, the term is negative 
(reduces the predicted translation rate). A neutral term means that CsrA binding the RNA 
causes no change to the structure. For a positive ΔGbound_structure, CsrA binding opens up 
the RBS site and would activate translation. 
In addition to ΔGbound_structure factoring in the structural changes in the RNA due to 
CsrA binding, an additional reduction to the translation rate was added to the model if 
CsrA was predicted to bind on the ribosome binding site (RBS). This condition is 
described as TIRon and is calculated below. 
    TIRon = TIR/e
(βΔGprotein_site_1) 
ΔGprotein_site_1 is the ΔG derived from the PWM for the 5 nucleotide binding site 
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This calculation of TIRon effectively alters the total free energy calculation to 
include a term for the energy to remove CsrA from a single position in the following 
manner: 
ΔGtotal = (ΔGmRNA:rRNA + ΔGstart + ΔGspacing  - ΔGstandby) - ΔGbound_structure
  - ΔGprotein_site_1 
CsrA binding sites that occur within the RBS sequence result in a significant 
reduction of translation. In this model, it is assumed that only one CsrA position will 
directly interfere with translation, even if both sites are positioned to do so.  
With the consideration of the RNA structure and the position of CsrA binding, the 
RBS Calculator provided an estimate for the translation rate of the mRNA when CsrA is 
bound and when it is not bound.  
It is important to understand that this model predicting the activity of CsrA on 
mRNA has two parts. The first part predicted an ensemble of potential CsrA binding 
sites, but the second part predicted how CsrA binding would affect the translation rate at 
only the most likely site. This is done for practical reasons. Given that the model predicts 
all potential binding sites, there will usually be one binding site combination that will 
inhibit translation. However, most of the predicted sites are not relevant under biological 
conditions, so the model only considers the most likely binding site.  The effectiveness of 
this model and the assumptions made in predicting the binding sites is discussed in the 
following sections. 
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4.2.2 Verification of the model using translation assay data  
This model provided two predictions: 1) the position on the mRNA that is most 
likely to bind CsrA with a relative estimate of affinity and 2) the effect that CsrA binding 
will have on translation. While the verification of the binding site of CsrA would require 
extensive in vitro experimentation, the 5’ translation assay presented in Chapter 3 would 
be the ideal method to evaluate the prediction of CsrA’s effect on translation. To evaluate 
our model with the data from the translation assay, it was necessary to make two major 
assumptions: 1) Any mRNA activity that was repressed at a minimum ratio of 1.5 
(fluorescence without CsrA/fluorescence with CsrA) is directly interacting with CsrA and 
2) the genes tested are representative of the whole population of interacting and 
non-interacting genes. With these considerations, all 5’UTR sequences that had 
measurable fluorescence values were evaluated using the three different CsrA binding 
assumptions discussed in Section 4.2.1.  
By evaluating the three models of CsrA binding site predictions, we were able to 
determine which factors are the most important to describing CsrA behavior. The first 
model assessed assumes that CsrA binds to only one position (named the Single site 
model). The second model allows for CsrA binding at two sites and neglects the value of 
dimerization (named the Two sites model), and the third model includes the estimation of 
dimerization (Dimer model). Table 4.2 presents the prediction of the ΔG of CsrA binding 
for each model, the prediction of translation activity with CsrA for each model, the 
observed ratio of repression by CsrA (fluorescence without CsrA/fluorescence with 
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CsrA), and the predicted ratio of fluorescence taken from the RBS Calculator predictions 
(only for the Dimer model of CsrA binding).  
 97 


































glgC 102.7 44.94 11884.95 -24.77 1 -20.18 1 -12.76 1 
pckA 415.4 36.77 46.37 -22.65 1 -19.13 1 -10.40 1 
glsA 1009.9 19.01 1.00 -21.81 2 -18.88 2 -10.56 2 
aidB 569.9 16.93 94.80 -19.51 1 -15.93 2 -9.10 2 
rseA 286.5 11.62 135.98 -24.42 1 -20.18 1 -10.56 2 
maeB 127.6 11.22 1298930.45 -23.06 1 -18.47 1 -9.94 1 
thiG 312.2 11.07 84.51 -15.78 1 -13.17 1 -6.99 2 
yidQ 121.6 11.07 1.00 -25.34 2 -23.87 2 -12.76 2 
yafQ 1699.9 10.50 304.18 -24.95 1 -21.27 1 -11.11 1 
mscS 95.6 10.02 2289764.33 -23.58 1 -19.23 1 -10.32 1 
uspG 224.7 9.13 199.52 -20.99 1 -17.74 1 -9.97 1 
deoD 180.3 8.93 499359.43 -24.69 1 -20.05 1 -11.14 1 
uidR 197.8 8.80 1.00 -21.12 2 -16.68 2 -8.71 2 
acnA 50.6 7.91 0.23 -21.00 2 -17.15 1 -9.59 2 
ydhQ 566.2 7.60 42244.48 -23.96 1 -20.28 1 -11.80 1 
frdB 891.1 7.46 16456.77 -26.82 1 -22.28 1 -12.76 1 
rnk  251.2 7.42 2112.61 -21.87 1 -18.39 1 -9.62 2 
hflK 618.4 7.38 31059.50 -24.27 1 -20.96 1 -10.56 1 
astD 249.1 7.04 1.00 -20.79 2 -17.80 1 -9.62 2 
poxB 35.715 6.79 47.12 -20.20 1 -17.98 2 -10.56 1 
nnr  514.4 6.65 477.05 -21.39 1 -17.37 1 -9.62 2 
gshB 241.9 6.61 6615.68 -24.83 1 -20.18 1 -10.56 1 
fucO 4203.3 6.22 2398.88 -26.72 1 -22.38 1 -12.76 1 
moaB 243 5.83 9.17 -23.98 1 -20.18 1 -12.76 1 
gstA 60.3 5.73 25.84 -22.07 1 -20.18 2 -12.76 2 
ucpA 1476.8 5.70 4.41 -23.64 1 -22.11 1 -11.95 1 
cysD 58.6 5.53 5782.56 -24.10 1 -19.86 1 -10.24 1 
cmk  166 5.26 105776.28 -23.62 1 -21.37 1 -10.81 1 
rnr  978.6 4.82 51.33 -20.12 1 -15.94 1 -7.97 1 
hemX 432.4 4.81 621513.45 -22.96 1 -19.24 1 -9.62 1 
ltaE 86.7 4.81 17225.49 -22.10 1 -18.94 1 -11.30 1 
glpR 217.1 4.79 309.86 -20.89 1 -17.91 2 -8.77 1 
entF 44.3 4.68 618517.85 -20.50 1 -15.76 1 -8.16 1 
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gadA 144.2 4.54 308278.76 -21.39 1 -17.67 1 -10.16 1 
ahr  545.8 4.31 48478.28 -25.65 1 -22.38 1 -12.76 1 
tnaA 19.4 4.25 7922232.31 -25.55 1 -20.90 1 -10.34 1 
pgaA 38.3 4.15 3.24 -27.06 1 -22.36 1 -11.45 1 
hfq 35 4.02 10493.75 -26.81 1 -22.57 1 -12.76 1 
entC 53 3.97 0.27 -19.48 2 -16.88 2 -9.62 2 
clpB 94.6 3.91 7.38 -17.77 1 -13.37 2 -6.89 2 
rpoS 111.7 3.83 1.00 -20.88 2 -16.93 2 -8.61 2 
uxaB 180.5 3.77 1.00 -20.27 2 -16.59 2 -9.24 2 
pgm  267.7 3.70 180704.53 -20.43 1 -19.77 1 -10.15 1 
tauD 320.9 3.63 232.83 -17.86 1 -14.41 1 -7.42 1 
gadB 123.2 3.55 6068021.53 -23.31 1 -18.97 1 -9.62 1 
proP 37.8 3.54 1796.10 -24.67 1 -20.18 1 -12.76 1 
dps  75.5 3.53 33.72 -19.87 1 -18.08 1 -8.46 1 
relA 103.2 3.42 5552297.06 -23.39 1 -20.72 1 -10.65 1 
icd  1776.9 3.41 7019309.68 -21.60 1 -17.59 1 -9.62 1 
ydeP 111.3 3.26 213.10 -19.24 1 -16.15 1 -9.38 1 
evgA 23 3.22 1.00 -20.91 2 -20.18 1 -12.76 2 
gstB 26.4 3.16 292520.98 -19.69 0 -15.89 0 -8.53 0 
sdhA 43 3.11 25.64 -19.19 1 -15.89 1 -8.47 2 
groL 565.1 2.99 3486871.84 -23.70 1 -19.62 1 -10.00 1 
ydjA 2115 2.99 86.30 -18.05 1 -13.51 1 -6.48 2 
rspB 15.1 2.93 4021512.13 -24.59 1 -20.77 1 -12.29 1 
hemG 23.5 2.92 0.28 -21.07 2 -18.51 2 -10.56 1 
yfgM 12 2.90 2418.35 -30.26 1 -25.52 1 -12.76 1 
nhaR 18.2 2.87 145487.60 -20.33 1 -17.57 1 -9.62 1 
csrA 131.4 2.71          
sdiA 25.7 2.69 366.80 -19.33 1 -17.19 1 -9.71 1 
ybeL 221.3 2.62 283.33 -20.00 0 -17.04 0 -9.62 0 
ybaL 18.4 2.51 0.03 -18.20 2 -17.33 2 -9.91 2 
fdoH 13.3 2.45 0.33 -22.63 2 -18.59 2 -10.62 2 
elaB 134.3 2.44 596.72 -19.42 1 -15.90 1 -7.97 1 
crp  55.8 2.33 0.96 -24.31 2 -20.18 2 -12.76 2 
cysJ 42 2.26 1.00 -17.10 2 -12.76 2 -7.42 2 
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cstA 58.2 2.22 567621.03 -22.57 1 -18.53 1 -10.56 1 
fabB 19.3 2.09 1.00 -24.49 2 -19.75 2 -12.76 2 
dkgA 2051.3 2.04 139813.34 -24.49 1 -21.22 1 -11.09 1 
ppc  182.5 2.02 396.71 -22.92 1 -19.24 1 -9.62 2 
pspA 63.2 2.02 59.15 -17.04 1 -12.80 1 -7.97 2 
yhiI 18 1.97 31338.45 -19.77 1 -16.77 1 -9.30 2 
ahpC 2868.2 1.96 2.05 -19.84 1 -17.59 1 -8.48 2 
uxaA 121.3 1.93 0.15 -19.44 2 -18.58 2 -10.61 2 
sucB 78 1.90 1023931.20 -24.36 0 -19.62 0 -11.35 0 
ppk  35.7 1.88 626.66 -23.93 1 -19.75 1 -10.13 1 
sucC 1867 1.81 3.81 -27.08 1 -22.38 1 -12.76 1 
yebE 1113.7 1.79 8204.50 -19.43 1 -14.69 1 -8.10 2 
truC 10.2 1.67 111.52 -20.49 1 -18.78 2 -9.46 2 
yaeP 22.8 1.64 5.94 -20.48 1 -16.80 1 -8.83 2 
glcB 336.2 1.64 57.42 -21.03 1 -17.86 1 -9.62 2 
dsrB 2365.3 1.63 4474338.32 -23.96 1 -20.28 1 -10.15 2 
cysK 305.7 1.61 23231.32 -22.50 1 -18.62 1 -10.65 1 
lsrF 966.5 1.61 1.25 -20.55 1 -18.33 1 -9.62 2 
ycaC 19.5 1.57 1.00 -18.41 0 -14.69 0 -7.51 0 
iscS 321.3 1.55 1.43 -23.94 1 -19.86 1 -10.56 2 
yecC 14.3 1.53 91.14 -23.53 1 -19.24 1 -9.62 1 
katG 1655.9 1.49 1.00 -16.40 4 -11.90 4 -6.13 4 
bfr  74.2 1.43 0.26 -18.33 4 -15.07 4 -7.97 4 
csiD 698.2 1.41 0.41 -20.84 4 -16.09 4 -9.23 4 
rodZ 23.6 1.40 1.00 -19.69 4 -19.04 4 -10.13 4 
pepT 1960.7 1.37 327.80 -20.94 3 -18.49 3 -9.36 0 
groS 1578.5 1.33 1.00 -20.84 4 -17.04 4 -9.62 4 
iscR 248.6 1.32 151.16 -21.64 3 -17.46 3 -9.49 4 
dnaK 859 1.27 1.00 -19.09 4 -17.83 3 -9.62 4 
flu  165.9 1.26 9576766 -25.04 0 -20.59 0 -12.27 0 
sucA 13.9 1.24 24006.25 -21.75 3 -18.03 3 -9.13 4 
aroG 271.6 1.22 0.39 -22.05 4 -17.71 4 -9.62 4 
fabI 279.2 1.20 130796.43 -23.01 3 -18.42 3 -8.80 3 
carB 54.5 1.16 650.83 -22.92 3 -19.24 3 -9.62 3 
yceD 46.9 1.14 1.98 -19.04 3 -17.00 3 -9.62 3 
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pntB 18.4 1.12 207.03 -19.41 3 -15.99 3 -8.02 3 
proB 8 1.12 0.26 -18.48 4 -15.94 3 -7.97 4 
fecA 44.7 1.10               
hchA 544.9 1.09 99829.30 -24.20 3 -19.46 3 -9.84 3 
yjbD 14.8 1.09 0.68 -20.88 4 -19.24 4 -9.62 3 
eno  29.7 1.08 1.00 -21.17 4 -16.48 4 -8.00 4 
talA 1257.6 1.06 1373178. -18.29 3 -14.49 4 -6.64 4 
mreB 12.3 1.03 0.76 -18.67 4 -14.49 3 -7.85 3 
uxaC 13.4 1.03 1982724. -23.42 3 -18.78 3 -9.62 4 
pflB 98 1.03 0.41 -22.76 4 -18.78 4 -10.46 4 
ydcS 535.2 1.00 1.00 -23.98 4 -20.73 3 -12.76 4 
cdd 80.3 0.99 766.38 -18.54 3 -14.00 3 -7.01 3 
yeaH 37.6 0.98 0.96 -18.52 4 -14.54 4 -7.52 3 
sdhB 132.9 0.95 233.27 -20.09 3 -15.39 3 -7.97 4 
wrbA 81.7 0.94 0.15 -23.15 4 -18.56 4 -9.62 4 
pdxB 36.5 0.93 5.58 -17.53 3 -14.31 3 -7.83 3 
metC 14.3 0.92 1.00 -17.50 4 -12.96 3 -6.48 4 
lpxC 33.8 0.91               
proS 84.6 0.89 426.84 -16.03 3 -11.45 3 -6.16 3 
glnS 83.1 0.88 1.00 -20.47 4 -17.59 4 -9.62 4 
katE 135.8 0.82 21.60 -22.69 3 -18.81 3 -9.58 3 
ompR 11.7 0.81 93.19 -20.50 3 -17.59 3 -9.62 4 
guaA 11.4 0.81 188.95 -21.87 3 -17.59 3 -9.62 4 
kdsA 129.6 0.80 21552.20 -23.28 3 -20.73 3 -11.11 3 
aroD 26.8 0.78 277.42 -20.23 3 -17.58 3 -9.62 3 
yqjD 2033.8 0.77 1.88 -21.73 3 -20.31 4 -10.07 3 
pta 10.7 0.76 1.86 -18.13 3 -16.08 3 -8.11 3 
uxuB 30.5 0.75 0.46 -17.77 4 -16.54 4 -8.61 4 
purM 133.1 0.73 1.00 -21.06 4 -18.46 4 -9.62 4 
fhuA 9.2 0.73 1.00 -14.18 4 -11.28 4 -6.45 4 
cspE 295.7 0.70 1.14 -21.82 4 -19.62 4 -10.00 4 
iaaA 42.2 0.70 233025.61 -23.07 3 -18.83 3 -9.62 3 
glmS 10.3 0.69 0.70 -22.61 4 -19.09 4 -9.96 4 
mtlD 328 0.65 297077.25 -20.28 3 -15.84 3 -7.85 3 
acs 1864.2 0.64 9.96 -18.71 3 -14.99 3 -8.51 3 
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manX 17 0.59 115465.61 -24.04 3 -20.69 3 -12.76 3 
ackA 7.2 0.16 1905.11 -16.15 3 -11.41 3 -6.99 3 
 
The table contains all active mRNAs tested by the 5’UTR assay and includes the 
observed fluorescence measurement, the observed ratio of CsrA repression, the 
predicted ratio of repression from the Dimer model of CsrA interactions, and the 
predicted ∆G of CsrA binding with the three evaluated model parameters (Single 
site, Two sites, and Dimer). The numbers in the prediction columns correspond to 
the following interpretation of the model prediction: 1 – inhibition predicted and 
observed, 2 – inhibition observed, but not predicted, 3 – inhibition not observed, 
but predicted, 4 – inhibition neither predicted nor observed, 0 – experimental data 
failed statistical significance test. 
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The first observation is that the predicted rates of repression are much greater than 
what is detectable in the translation assay. This effectively makes the predicted 
translation rate more of a binary prediction, as either CsrA represses translation or has no 
effect on translation. It is inappropriate to compare predictions of translation activation to 
the observations due to fact that the observed activation of targets is likely an indirect 
effect of CsrA changing cell growth rate (discussed in Chapter 3). For the purposes of 
evaluating the model, only the inhibition predictions are verifiable.  
4.2.3 The Dimer model of CsrA binding is the most accurate prediction of CsrA 
activity 
 
 The first question that needed to be answered was whether the assumptions made 
for the CsrA binding site predictions are valuable. The three different binding site 
predictions are 1) CsrA binding to only one site, 2) CsrA binding to two sites, and 3) 
CsrA binding to two sites with dimerization. If the prediction of CsrA affinity is ignored 
and the only consideration is the prediction of translation inhibition for the most likely 
CsrA binding site, then the models behave as summarized in Table 4.3.  
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Table 4.3: Comparison of observed and predicted inhibition of targets with three different 
CsrA binding models  
  
As can be seen in Table 4.3, the Single site prediction model is capable of 
identifying 57% of the inhibited targets that we observed as inhibited and identifies 52% 
of all the targets that were unaffected by CsrA as potential targets. This indicates that the 
single CsrA binding site prediction fails to predict a large percentage of mRNA targets 
and performs poorly when identifying targets from non-targets. This shows that a simple, 
single site model of CsrA-target interactions is inadequate to describing the physical 
system.  
The Two sites model has a slight selective advantage in its overall ability to 
identify targets and non-targets, but this advantage is smaller than the Dimer model. 
When the dimerization term is included, the predicted binding sites have a 78% chance of 
identifying a gene inhibited by CsrA, but will falsely identify 56% of non-targets. While 
the overall numbers of targets correctly or incorrectly identified as CsrA targets is similar 
in both the dimer and two site models, the consideration of dimerization does improve the 


























Dimer model 65 18 29 23 0.78 0.56 
Two sites model 62 21 31 21 0.75 0.60 
Single site model 47 36 27 25 0.57 0.52 
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the most complete description of CsrA binding. However, the overall prediction 
generates too many false positives to be useful to predict mRNA targets of CsrA.  
This failure to predict targets based on the translation prediction alone is a direct 
result of the assumption that CsrA has to bind the mRNA target. In the prediction of 
CsrA bound translation rate, the model is effectively estimating the translation rate when 
the concentration of CsrA is infinite. Under this estimation, CsrA would be forced to bind 
to transcripts at exceptionally weak binding sites that would not be feasible under normal 
physiological conditions or the conditions tested in the 5’UTR translation assay (Chapter 
3.2.1). Given that CsrA binds to a sequence similar to the Shine-Delgarno site, at high 
enough concentrations, CsrA will likely inhibit most translation initiation sites.  For this 
reason, it is necessary to consider the affinity of the predicted CsrA target when 
considering the validity of the model. 
4.2.4 Population of correctly predicted targets have stronger ∆G of CsrA binding 
Given that this model has two distinct parts, one predicting translation and the 
other predicting CsrA affinity to specific binding sites, we wanted to investigate if the 
predicted putative strength of the CsrA interaction was related to the specificity of the 
prediction. To answer this question, the cumulative distribution of the target’s CsrA 
affinity was plotted for all four predictive outcomes in each model variation presented in 





Figure 4.2: Cumulative distribution for tested mRNAs using different models for 



































∆G (RT units) 
A. Cumulative distribution of ∆G for predicted CsrA 

























∆G (RT units) 
B. Cumulative distribution of ∆G for predicted CsrA 
binding sites using the Two sites model 
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Figure 4.2: Cumulative distribution for tested mRNAs using different models for 
calculating CsrA affinity (continued) 
 
 
These are the cumulative distributions of the predicted ∆G of CsrA binding for 
the four possible predictive outcomes from the three methods to predict CsrA 
binding. 
A) Dimer model  
B) Two sites model  
C) Single site model 
- Blue diamond curves represent the distribution of targets that are positively 
identified. 
- Red boxes are the population where the model failed to predict inhibition. 
- Green triangles are the population that was falsely identified as CsrA targets. 
- Purple Xs are the population that was correctly identified as having no 


























∆G (RT units) 
C. Cumulative distribution of ∆G for predicted CsrA 
binding using the Single site model 
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 As can be seen in the cumulative distribution of positively identified targets, there 
is a clear differentiation in the distribution of the population of correctly identified targets 
and incorrectly identified targets at any predicted ∆G of CsrA binding. A comparison in 
of the average value of ∆G found in the population appears in Table 4.4.  
 
Table 4.4: Average predicted ∆G of CsrA binding for each model  
  
Dimer Model Two Site Model One Site Model 



















1 -22.31 ±2.70 -18.83 ±2.42 -10.57 ±1.42 -21.93 ±2.60 
2 -20.70 ±2.20 -17.46 ±2.53 -9.52 ±1.61 -20.26 ±1.86 
3 -20.62 ±2.46 -16.78 ±2.67 -8.86 ±1.53 -20.52 ±2.46 
4 -20.20 ±2.64 -17.31 ±2.58 -9.00 ±1.62 -20.20 ±2.64 
 
Each column contains the average ∆G of CsrA with plus/minus standard deviation 
(in arbitrary RT units) for the population’s predicted outcome of that method. The 
number corresponding to the Predicted Populations are identical to those 
described in Table 4.2. The fourth column represents the average populations 
from the Dimer model while excluding the targets that were identified based on 
motif predictions.  
As can be seen by the average values of the populations, the targets that are 
predicted accurately (Population #1) have a considerably higher ∆G of CsrA binding than 
all other populations. This difference is significant with a p-value below 0.05, as 
determined by the Student’s t-test. For a comparison, the Dimer model predicts that 
randomized segments of RNA of the approximate length of the 5’UTRs tested (200 
nucleotides) have an average ∆G of CsrA binding of 19.34±2.18 (RT units). This value 
was calculated from 100 randomized sequences.  
Since some of the targets evaluated were selected based on the similarity of the 
sequence to the predicted motif, these targets were removed from the average calculated 
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in column 4. While the removal of these targets does lower the overall ∆G of CsrA 
binding, there is still a bias for stronger binding in the accurately predicted targets over 
the falsely identified targets. By excluding these targets from the population, it is clear 
that this bias in binding free energy was not artificially introduced by our model 
assumptions. The bias for higher predicted binding in the true target clearly demonstrates 
that the model is identifying the right parameters to consider when predicting CsrA 
binding. 
4.2.5 Accurate predictions of mRNA targets using ∆G reveals the significance of the 
position weight matrix  
For this model to be applied as a predictive method for identifying CsrA regulated 
genes, it is necessary to consider when the free energy of CsrA binding will maximize 
correct target predictions and minimize incorrect targets predictions. For the Dimer 
model, this maximum difference between the percent of true positive and false positive 
predictions occurs at -23.5 (RT units), as seen in Figure 4.2. At this cut off free energy, 
the Dimer model selects 42% of the population of the true positives and 13% of the false 
positive targets. The different models were evaluated at the following predicted free 
energy of CsrA binding: Dimer model - -23.5 (RT units), Two sites model - -20.0 (RT 
units), Single site model - -10.5 (RT units).  
When these free energy considerations are applied to targets tested in our 
translation assay, we noticed that many of the targets identified are identical with respect 
to the model. For example, comparing the Dimer model and the Single site model, 26 
mRNA targets are identified by both models, 11 targets are predicted exclusively by the 
dimer model, and 5 targets are exclusive predictions of the Single site model.  
 Interestingly, the Single site model performed almost as well the Dimer model 
when it came to the most accurate prediction of CsrA targets. This can be explained when 
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one considers the free energy model used to make this prediction. The single site model 
has a minimum free energy prediction of -12.76 (RT units) when all nucleotides match 
the PWM (Table 4.1).  A free energy prediction of -10.5 in the single site model means 
that only three possible CsrA binding sites could be considered, AAGGA, AAGGN, or 
ANGGA. This suggests that having a strong CsrA binding site in a position that affects 
ribosome binding is a very strong indicator of a gene being a target of CsrA.   
4.2.6 Prediction of CsrA affinity has qualitative significance  
Understanding how CsrA is capable of regulating so many cellular factors is 
critical towards fully understanding the complexity of global CsrA-mediated 
regulation.  One hypothesis is that CsrA displays differential affinities for the targets it 
regulates allowing for CsrA to be specifically titrated to affect some genes but not others. 
While the previous section demonstrated that the predicted affinity of the CsrA 
interaction had a relationship to correct target predictions, we wanted to evaluate if the 
predicted affinity also had a physiological significance that could explain global CsrA 
regulation.  
To assess the physiological relevance of the free energy predictions, we devised a 
means of altering CsrA expression that would alter the fluorescence of the 5’UTR 
translation assay. The rationale for this assay is as follows: 1) Fluorescence from a 
specific mRNA will display one activity when CsrA is bound and a different activity 
when CsrA is not bound. 2) The ratio of bound and unbound mRNA will follow a 
standard sigmoidal relationship dependent on the concentration of CsrA, the mRNA, and 
their affinity towards each other. 3) Observable fluorescence will reflect the ratio of the 
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bound and unbound mRNA transcripts. Using this logic, one would expect that 
population’s fluorescence, with a specific mRNA, will resemble a sigmoidal binding 
curve dependent on the amount of free CsrA present and the affinity that CsrA has to the 
mRNA. To test this system, CsrA expression was titrated with glgC (a high affinity 
prediction) and aidB (a low affinity prediction). 
For this data, the fluorescence ratio is representative of the ratio of bound to 
unbound mRNA transcript with 0% bound mRNA being defined as repression ratio of 1 
and 100% bound mRNA having a value between 8-16. This value is dependent on the 
rate of cell division after induction of CsrA (see Methods 4.4.1 for more details).  
Expressing CsrA across a thousand fold range approximately revealed the 
characteristic sigmoidal increase in repression level for both glgC and aidB (Figure 4.3). 
For comparison purposes, an approximated sigmoidal binding curve is drawn to fit the 
data.  Specifically, the equivalence point for aidB is shifted towards higher expression 
levels of CsrA with respect to glgC, suggesting that glgC is more sensitive (has a higher 
affinity) to CsrA than aidB. This is evidence that CsrA is capable of preferentially 
recognizing targets at specified concentrations and that our estimations for CsrA affinity 
to a target have physiological significance relative to each other.  
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Figure 4.3: Relative repression ratios of select targets in response to alterations of CsrA 
expression 
(A) Expression profile of glgC mRNA in 5’UTR translation assay 




This chapter presents a model devised from first principles of CsrA binding and 
translation initiation to predict the free energy of potential CsrA interactions and the 
effects that the interactions will have on a specific gene. While each of the three models 
over estimates the total number of mRNAs affected by CsrA, consideration of the 
predicted strength of the CsrA interaction allows for predictions that reduce the expected 
number of false positives. Currently, the Dimer model is being applied to the E. coli 
genome and will be used to predict novel targets of CsrA. A more complete knowledge of 
the CsrA regulated genes will greatly improve a current hole in the understanding of 
cellular regulation, allowing for a more integrated understanding of the interplay between 
transcriptional-translational regulation.  
Furthermore, the comparison of the different models to predict CsrA binding 
demonstrates the missing information in the mechanistic understanding of CsrA based 
regulation. While the models demonstrate that the presence of an AAGGA sequence near 
the RBS site was a strong indicator of CsrA based regulation, it is far from a presenting a 
complete understanding of CsrA based prediction. This work emphasizes the diversity of 
CsrA based interactions. While many genes analyzed showed CsrA binding patterns that 
correlate the current understanding of CsrA-RNA interactions, many genes did not.  
In particular, thiG mRNA sequence had a very low predicted affinity for CsrA but 
displayed very strong regulation by CsrA in the translational assay. Genes that 
significantly deviate from the predicted interaction patterns represent interesting test 
subjects that can be analyzed to better the overall understanding of CsrA-RNA 
interactions and improve the predictive binding model. A more thorough characterization 
of this mRNA’s interaction with CsrA would be in order. At the very least, this 
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information should inform the design of synthetic RBS sequences to avoid containing an 
AAGGA sequence to prevent unintentional regulation.   
Additionally, the models presented provide a framework to explain the overall 
strategy that the cell employs when using CsrA to regulate entire pathways. The 
implication that CsrA is specifically titrated to unique genes suggests that CsrA based 
regulation is more nuanced than a binary regulation-no regulation understanding of CsrA-
mRNA interactions. This finding is reinforced by recently published work that has shown 
that the binding of RsmE (CsrA) to its sRNA follows a precise sequence and is based on 
the concentration of the available mRNA (108). This information that the sRNA 
competitor of a CsrA like protein has specific titratable levels of protein binding strongly 
suggests that the availability of free protein is specifically manipulated to allow the 
regulation of certain mRNAs before regulating others. We hypothesize that genes that 
produce proteins related to specific tasks will have similar affinities to CsrA, thereby 
allowing CsrA to have a hierarchical control over specific subsets of genes. This 
hypothesis will be tested as part of the ongoing work to apply this model to the genome 
of E. coli.  
4.4 METHODS 
4.4.1 Evaluation of CsrA affinity through titration of fluorescence signal 
Titration of CsrA concentration was achieved through modification of the CsrA 
expression system employed in the 5’ UTR assay discussed in Chapter 3.  Eight RBS 
sites were created to alter the expression of CsrA from the vector used in the mentioned 
assay. The RBS sequences were calculated by the RBS Calculator to express the protein 
across a thousand-fold range of the original system. The eight sites have computationally-
determined putative levels of CsrA expression of 9000, 2000, 1000, 850, 750, 500, 350, 
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and 200 (with 9000X being the predicted rate of expression from the original plasmid). 
These sites were created on primers that amplified CsrA so that they could be ligated in 
to the plasmid using standard techniques. A list of the 8 RBS sequences and the primers 
used to attach them to CsrA appear in Appendix Table A.1.  
Using these modifications to the CsrA expression system, the 5’UTR-translation 
assay was carried out for each CsrA expression modification. In these tests, the ratio of 
repression is measured as in Chapter 3 with the exception that all fluorescence values 
were normalized to the highest fluorescence measured. In this case, that value 
corresponded to the fluorescence measured when the weakest RBS (200) was uninduced. 
The maximum ratio of fluorescence from the uninduced and the induced CsrA conditions 
signals 100% CsrA-mRNA binding. This ratio is related to the number of cell divisions 
that occur to allow depletion of the fluorescence signal (as described in Chapter 3). In this 
case, the maximum value is between 8 and 16.   
For these experiments, the activity of the RBS (and overall concentration of 
CsrA) should be related to the putative strength of the RBS and be proportional to the 
concentration of the mRNA for CsrA. For induced and uninduced measurements, the 
amount of transcript present was viewed as 100% available following induction and 1% 
available for uninduced cells. These estimates for the leakiness of the CsrA promoter 
come from previously published characterization of the system (93). Additionally, the 
putative RBS strength is expected to have a potential error of 2X the putative value 
(between 50% and 200%). 
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Chapter 5 
Conclusion and Future Directions 
The work presented in this dissertation represents the development of unique 
applications and techniques for the study of RNA-protein interactions and resulted in the 
advancement of the current understanding of CsrA-RNA interactions.  
Chapter 2: Development of a Tri-molecular Fluorescent Complementation 
assay (TriFC) to detect regulatory RNA-protein interactions 
Through the application of tri-molecular fluorescence complementation (TriFC) 
and some basic protein and RNA design principles, we have demonstrated how it is 
possible to visualize RNA-protein interactions in vivo and have demonstrated that the 
method is sensitive enough to detect mutations that alter the affinity of the interaction. As 
this tool represents a method to detect the interaction of CsrA and CsrB, it would be 
extremely useful to adapt this tool to so that the modified CsrB molecule was expressed 
under the natural system. If this could be done with TriFC, one could imagine that it 
would be possible to subject the cell to extracellular stresses to understand the conditions 
that activate CsrB. 
 Applications of the TriFC method could be extended to probing RNA-protein 
interfaces. The TriFC fluorescence output was shown to be sensitive to mutations in CsrA 
that affect the affinity of the RNA protein interaction. Using mutational libraries of the 
target RNA or protein, it would be possible to identify mutations that negatively affect 
the RNA-protein interaction that could be used to elucidate the structure of the 
RNA- protein interaction.   
Chapter 3: Translational assay for characterizing CsrA regulation on mRNA 
transcripts with interaction validation using TriFC 
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This work presented one of the first largescale characterizations of mRNA-CsrA 
interactions through the application of a 5’UTR translational fusion. In this assay, the 
5’UTR and a section of the coding sequence of an mRNA of interest was expressed as a 
translational fusion to GFP. The fluorescence of the system is directly related to the 
translational activity of the mRNA being tested. If the mRNA was a target of CsrA, 
induction of CsrA alters the translation activity of the target. This work is one of the first 
attempts at quantifying the effect of CsrA on mRNA activity and has directly introduced 
evidence that mRNA-CsrA interactions exist beyond a simple binary output of regulation 
vs no regulation. Indeed, this work has demonstrated that specific sequences of RNA 
show gradations of responses to CsrA. 
The concept that separate RNAs can have a gradient of responses to CsrA should 
be pursued further. The evidence suggests that CsrA does not totally inhibit the mRNA 
targets that it interacts with. One possible explanation for this observation is that CsrA 
has low affinity for the mRNA target and does not completely bind all the available 
mRNA. This explanation could explain how CsrA can differentially affect so many 
mRNA targets. Another explanation for incomplete inhibition could be that CsrA binding 
to an mRNA target causes a partial shift in its translational activity. This would be a 
unique mechanism to biological systems, which tend to be simplified as either inhibiting 
vs non-inhibiting. If this interaction can be verified, it may change the current 
understanding of cellular regulation. 
Furthermore, the TriFC tool was applied to verify mRNA-CsrA target 
interactions. With some relatively minor changes to the design of the RNA target 
molecule that directs TriFC, we were able to create a system that allowed for in vivo 
screening of mRNA-CsrA interactions. This work provided the first direct evidence for 
mRNA-CsrA interactions of 19 targets, including the sigma factor rpoS.  While this work 
 117 
expands the current knowledge of mRNA targets of CsrA, the knowledge of CsrA 
regulation is far from complete. Further characterization of the CsrA network should 
continue to inform and improve models of regulation. 
Chapter 4: A first principles model of CsrA binding and activity with 
experimental validation  
A model was created using the primary principles of RNA-CsrA interactions to 
predict RNA-CsrA interaction affinity and to predict the effect that CsrA would have on 
translation initiation. The accuracy of this model was compared to experimental data 
gathered from the 5’UTR translation assay presented in Chapter 3. Comparison of the 
model predictions to the translational assay data clearly demonstrates that the current 
understanding of mRNA-CsrA interactions is adequate to describe interaction behavior 
and has predictive power to assess the likelihood that a given sequence may be a target of 
CsrA. However, the data presented shows that certain sequences represent a clear 
deviation from the accepted understanding of mRNA-CsrA interactions. Further study of 
the genes that didn’t comply with current model could greatly improve what is known of 
CsrA-mRNA interactions.  
Evaluation of this model’s prediction of mRNA-CsrA interaction suggested that 
mRNA sequences are uniquely titrated by the concentration of CsrA to allow finely tuned 
response of targets based on the availability of CsrA. This model and data from the 
5’ translation assay strongly supports the current hypothesis that mRNA-CsrA affinity is 
the main mechanism for CsrA fine tuning of gene expression. Recent work investigating 
the relationship between an analogue of CsrA and its regulatory RNA has shown that the 
RNA-protein interaction is highly tuned and ordered as to allow protein binding at 
specific locations only when the protein concentration is high enough (108). This 
information taken with the findings that specific mRNAs have a concentration and 
 118 
sequence dependent response to CsrA is strong evidence that CsrA availability can be 
tuned to affect specific targets and pathways. Further experimentation with CsrA should 
strive to demonstrate that the cell employs condition specific titration of CsrA 
concentration to target the mRNAs needed for specific responses.  
This method of genetic control could also be implemented in engineered 
pathways. Using the concepts of the RNA binding molecules and the model presented to 
predict CsrA-mRNA interactions, it should be possible to design novel mRNA sequences 
designed to work with orthologous RNA binding proteins to give tunable 
post-transcriptional control of translation initiation.      
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SpeI/SphI CACTACTAGTGCCTGTCGGCAAAGGG AACTGAGCATGCAGGCATCCGGCCCAAAAC 
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Table A.3 TriFC plasmid modification 
TriFC 





















The presented sequence is the modification made to the plasmid pCsrA-NYFP+2MS2bd. 
The underlined sequences are the cut sites for endonucleases SpeI, SphI, and AatII. The 
sequence was added to the plasmid between the SpeI and AatII sites. The italicized 
sequence is that of mStrawberry. All TriFC plasmids were created by inserting the 
sequence from Appendix A.1 between the cut sites for SpeI and SphI. 
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Table A.4 RBS modification to CsrA expression system 
CsrA Expression 




















This table represents the changes made to the CsrA expression system used in the 
titration assay. The original system uses the plasmid pHL600 (94) and is presented in the 
first entry. The expression system was modified by the insertion of the sequence designed 
by the RBS Calculator (104) between the XmaI cut site (cccggg) and the coding sequence 
for CsrA (bold). The putative RBS strength (arbitrary units) is given in the name of the 
system. The original pHL600 plasmid had a putative strength of 9000 (arbitrary units) as 
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